
<html lang="en"     class="pb-page"  data-request-id="c60535bd-5818-4ddc-ac6e-5761dd1f4abd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01156;issue:issue:10.1021/jmcmar.2016.59.issue-23;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor" /></meta><meta name="dc.Creator" content="Hirosato  Ebiike" /></meta><meta name="dc.Creator" content="Naoki  Taka" /></meta><meta name="dc.Creator" content="Masayuki  Matsushita" /></meta><meta name="dc.Creator" content="Masayuki  Ohmori" /></meta><meta name="dc.Creator" content="Kyoko  Takami" /></meta><meta name="dc.Creator" content="Ikumi  Hyohdoh" /></meta><meta name="dc.Creator" content="Masami  Kohchi" /></meta><meta name="dc.Creator" content="Tadakatsu  Hayase" /></meta><meta name="dc.Creator" content="Hiroki  Nishii" /></meta><meta name="dc.Creator" content="Kenji  Morikami" /></meta><meta name="dc.Creator" content="Yoshito  Nakanishi" /></meta><meta name="dc.Creator" content="Nukinori  Akiyama" /></meta><meta name="dc.Creator" content="Hidetoshi  Shindoh" /></meta><meta name="dc.Creator" content="Nobuya  Ishii" /></meta><meta name="dc.Creator" content="Takehito  Isobe" /></meta><meta name="dc.Creator" content="Hiroharu  Matsuoka" /></meta><meta name="dc.Description" content="The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases regulates multiple biological processes, such as cell proliferation, migration, apoptosis, and differentiation. Vari..." /></meta><meta name="Description" content="The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases regulates multiple biological processes, such as cell proliferation, migration, apoptosis, and differentiation. Vari..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 29, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01156" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01156" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01156" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01156" /></link>
        
    
    

<title>Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01156" /></meta><meta property="og:title" content="Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0017.jpeg" /></meta><meta property="og:description" content="The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases regulates multiple biological processes, such as cell proliferation, migration, apoptosis, and differentiation. Various genetic alterations that drive activation of the receptors and the pathway are associated with tumor growth and survival; therefore, the FGFR family represents an attractive therapeutic target for treating cancer. Here, we report the discovery and the pharmacological profiles of 8 (CH5183284/Debio 1347), an orally available and selective inhibitor of FGFR1, FGFR2, and FGFR3. The chemical modifications, which were guided by 3D-modeling analyses of the inhibitor and FGFRs, led to identifying an inhibitor that is selective to FGFR1, FGFR2, and FGFR3. In in vitro studies and xenograft models in mice, 8 shows antitumor activity against cancer cell lines that harbor genetically altered FGFRs. These results support the potential therapeutic use of 8 as a new anticancer agent." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01156"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01156">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01156&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01156&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01156&amp;href=/doi/10.1021/acs.jmedchem.6b01156" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10586-10600</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01063" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01208" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hirosato++Ebiike">Hirosato Ebiike</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Naoki++Taka">Naoki Taka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masayuki++Matsushita">Masayuki Matsushita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masayuki++Ohmori">Masayuki Ohmori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyoko++Takami">Kyoko Takami</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ikumi++Hyohdoh">Ikumi Hyohdoh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masami++Kohchi">Masami Kohchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tadakatsu++Hayase">Tadakatsu Hayase</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroki++Nishii">Hiroki Nishii</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenji++Morikami">Kenji Morikami</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshito++Nakanishi">Yoshito Nakanishi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nukinori++Akiyama">Nukinori Akiyama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hidetoshi++Shindoh">Hidetoshi Shindoh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nobuya++Ishii">Nobuya Ishii</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takehito++Isobe">Takehito Isobe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroharu++Matsuoka">Hiroharu Matsuoka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#61040308080a04091312210209140600084c110900130c4f020e4f0b11"><span class="__cf_email__" data-cfemail="c2a7a0ababa9a7aab0b182a1aab7a5a3abefb2aaa3b0afeca1adeca8b2">[email protected]</span></a>. Phone: +81 467 47 6034.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01156&amp;href=/doi/10.1021%2Facs.jmedchem.6b01156" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10586–10600</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 7, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 August 2016</li><li><span class="item_label"><b>Published</b> online</span>29 November 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 December 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01156" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01156</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10586%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHirosato%2BEbiike%252C%2BNaoki%2BTaka%252C%2BMasayuki%2BMatsushita%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D23%26contentID%3Dacs.jmedchem.6b01156%26title%3DDiscovery%2Bof%2B%255B5-Amino-1-%25282-methyl-3H-benzimidazol-5-yl%2529pyrazol-4-yl%255D-%25281H-indol-2-yl%2529methanone%2B%2528CH5183284%252FDebio%2B1347%2529%252C%2BAn%2BOrally%2BAvailable%2Band%2BSelective%2BFibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitor%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10600%26publicationDate%3DDecember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01156"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2475</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01156" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hirosato&quot;,&quot;last_name&quot;:&quot;Ebiike&quot;},{&quot;first_name&quot;:&quot;Naoki&quot;,&quot;last_name&quot;:&quot;Taka&quot;},{&quot;first_name&quot;:&quot;Masayuki&quot;,&quot;last_name&quot;:&quot;Matsushita&quot;},{&quot;first_name&quot;:&quot;Masayuki&quot;,&quot;last_name&quot;:&quot;Ohmori&quot;},{&quot;first_name&quot;:&quot;Kyoko&quot;,&quot;last_name&quot;:&quot;Takami&quot;},{&quot;first_name&quot;:&quot;Ikumi&quot;,&quot;last_name&quot;:&quot;Hyohdoh&quot;},{&quot;first_name&quot;:&quot;Masami&quot;,&quot;last_name&quot;:&quot;Kohchi&quot;},{&quot;first_name&quot;:&quot;Tadakatsu&quot;,&quot;last_name&quot;:&quot;Hayase&quot;},{&quot;first_name&quot;:&quot;Hiroki&quot;,&quot;last_name&quot;:&quot;Nishii&quot;},{&quot;first_name&quot;:&quot;Kenji&quot;,&quot;last_name&quot;:&quot;Morikami&quot;},{&quot;first_name&quot;:&quot;Yoshito&quot;,&quot;last_name&quot;:&quot;Nakanishi&quot;},{&quot;first_name&quot;:&quot;Nukinori&quot;,&quot;last_name&quot;:&quot;Akiyama&quot;},{&quot;first_name&quot;:&quot;Hidetoshi&quot;,&quot;last_name&quot;:&quot;Shindoh&quot;},{&quot;first_name&quot;:&quot;Nobuya&quot;,&quot;last_name&quot;:&quot;Ishii&quot;},{&quot;first_name&quot;:&quot;Takehito&quot;,&quot;last_name&quot;:&quot;Isobe&quot;},{&quot;first_name&quot;:&quot;Hiroharu&quot;,&quot;last_name&quot;:&quot;Matsuoka&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;10586-10600&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01156&quot;},&quot;abstract&quot;:&quot;The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases regulates multiple biological processes, such as cell proliferation, migration, apoptosis, and differentiation. Various genetic alterations that drive activation of the receptors and the pathway are associated with tumor growth and survival; therefore, the FGFR family represents an attractive therapeutic target for treating cancer. Here, we report the discovery and the pharmacological profiles of 8 (CH5183284/Debio 1347), an orally available and selective inhibitor of FGFR1, FGFR2, and FGFR3. The chemical modifications, which were guided by 3D-modeling analyses of the inhibitor and FGFRs, led to identifying an inhibitor that is selective to FGFR1, FGFR2, and FGFR3. In in vitro studies and xenograft models in mice, 8 shows antitumor activity against cancer cell lines that harbor genetically altered FGFRs. These results support the potential therapeutic use of 8 as a new anticancer agent.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01156&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01156" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01156&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01156" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01156&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01156" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01156&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01156&amp;href=/doi/10.1021/acs.jmedchem.6b01156" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01156" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01156" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01156%26sid%3Dliteratum%253Aachs%26pmid%3D27933954%26genre%3Darticle%26aulast%3DEbiike%26date%3D2016%26atitle%3DDiscovery%2Bof%2B%255B5-Amino-1-%25282-methyl-3H-benzimidazol-5-yl%2529pyrazol-4-yl%255D-%25281H-indol-2-yl%2529methanone%2B%2528CH5183284%252FDebio%2B1347%2529%252C%2BAn%2BOrally%2BAvailable%2Band%2BSelective%2BFibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D23%26spage%3D10586%26epage%3D10600%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/jmcmar.2016.59.issue-23/20161208/jmcmar.2016.59.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases regulates multiple biological processes, such as cell proliferation, migration, apoptosis, and differentiation. Various genetic alterations that drive activation of the receptors and the pathway are associated with tumor growth and survival; therefore, the FGFR family represents an attractive therapeutic target for treating cancer. Here, we report the discovery and the pharmacological profiles of <b>8</b> (CH5183284/Debio 1347), an orally available and selective inhibitor of FGFR1, FGFR2, and FGFR3. The chemical modifications, which were guided by 3D-modeling analyses of the inhibitor and FGFRs, led to identifying an inhibitor that is selective to FGFR1, FGFR2, and FGFR3. In in vitro studies and xenograft models in mice, <b>8</b> shows antitumor activity against cancer cell lines that harbor genetically altered FGFRs. These results support the potential therapeutic use of <b>8</b> as a new anticancer agent.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tyrosine phosphorylation is a critical event in the signal transduction that is mediated by growth factor, and the protein tyrosine kinases are key components of the phosphorylation process. Several molecular targeted kinase inhibitors have been launched, such as epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> erb-b2 receptor tyrosine kinase 2 (HER2) inhibitor (lapatinib),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> breakpoint cluster region abelson tyrosine kinase (BCR-ABL) inhibitors (imatinib and dasatinib),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> B-RAF inhibitors (vemurafenib and dabrafenib),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and anaplastic lymphoma kinase (ALK) inhibitors (crizotinib and alectinib).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> While these kinase inhibitors that can treat patients according to their genetic status have contributed remarkable progress to cancer therapy, these drugs cannot cover all tumors, and the need to treat tumors harboring other genetic alterations still remains.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Thus, the potential therapeutic strategy using a molecular targeted drug to satisfy the unmet medical needs of a variety of cancers harboring novel genetic alterations has attracted attention over the years.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">In cancer, genetic alterations that constitutively activate FGFR, such as amplification and mutation, drive activation of the receptors and the pathway in several tumor types and are known to be associated with cell growth, angiogenesis, cell migration, invasion, and metastasis (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Several FGFR inhibitors targeting multiple kinases have been reported and are currently under clinical trial. While these drugs show some clinical benefits in patients that show positive for <i>FGFR</i> genetic alterations, some of the drugs, such as dovitinib (TKI258,<a onclick="showRef(event, 'cit6a'); return false;" href="javascript:void(0);" class="ref cit6a">(6a)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and cediranib (AZD2171,<a onclick="showRef(event, 'cit6b'); return false;" href="javascript:void(0);" class="ref cit6b">(6b)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), also target kinase insert domain receptor (KDR), which causes grade 3/4 hypertension, and dose limiting toxicity has been observed in a clinical trial.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Since compounds that are selective to one target kinase can potentially claim a more favorable toxicity profile than multitargeted compounds, selective and potent FGFR inhibitors are required. Currently, several FGFR-selective inhibitors, such as <b>21</b> (AZD4547)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and <b>22</b> (NVP-BGJ398)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), are under clinical trials targeting patients who have <i>FGFR</i> genetic alterations. These inhibitors, as well as the FGFR-selective inhibitor <b>20</b> (PD173074),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> share a common 3,5-dimethoxy-phenyl ring that interacts with the backpocket region of the FGFR, according to X-ray structures of the binary complex of FGFR with each inhibitor.<a onclick="showRef(event, 'ref8 ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref11">(8, 9, 11)</a> Since it is possible that a common single mutation, such as the gatekeeper mutation, is causing resistance to these inhibitors,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a potential strategy to overcome this issue is the rational design of a novel inhibitor with a different chemical scaffold.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Genetic Alteration and Amplification of <i>FGFR</i>’s and Related Cancers<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">gene</th><th class="colsep0 rowsep0" align="center">alteration</th><th class="colsep0 rowsep0" align="center">prevalence</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>FGFR1</i></td><td class="colsep0 rowsep0" align="left">amplification</td><td class="colsep0 rowsep0" align="left">squamous NSCLC (20%), breast (10%), ovarian (∼5%), bladder (3%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><i>FGFR2</i></td><td class="colsep0 rowsep0" align="left">amplification</td><td class="colsep0 rowsep0" align="left">gastric (10%), breast (4% of triple-negative cases)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutation</td><td class="colsep0 rowsep0" align="left">endometrial (12%), squamous NSLC (5%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><i>FGFR3</i></td><td class="colsep0 rowsep0" align="left">mutation</td><td class="colsep0 rowsep0" align="left">bladder (50–60% nonmuscle invasive type, 10–15% invasive type)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">translocation</td><td class="colsep0 rowsep0" align="left">myeloma (15–20%)</td></tr></tbody></table></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This report describes the optimization program that led to identifying the novel inhibitor (<b>8</b>, (CH5183284/Debio 1347)), which potently and selectively inhibits the FGFR family of receptor tyrosine kinases and which is currently in Phase I clinical trial.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of aminopyrazole derivatives <b>1</b>–<b>3</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Cyanomethylation of commercially available esters (intermediate b) with acetonitrile anion, which had been generated by treating acetonitrile (MeCN) with lithium hexamethyldisilazide (LHMDS) in THF at −78 °C, provided cyanomethyl compounds (intermediate c). The intermediate c that was available commercially or obtained above was treated with dimethylformamide dimethyl acetal (DMF-DMA) and yielded enamines (intermediate d). The aminopyrazoles were formed by treating the intermediate d with aryl hydrazine hydrochlorides at 100 °C. The synthesis of indole derivatives is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Because a protective group at 1-position of indole gave more selective cyclization to aminopyrazole, a benzenesulfonyl (Bs) group or a tosyl (Ts) group was introduced in the synthesis of indole derivatives (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The functional groups at 5-position or 6-position of indoles were introduced in advance to form the aminopyrazole ring, except for the sulfone compound (<b>16</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The methanesulfonyl group in <b>16</b> was introduced to the aminopyrazole derivative (<b>16c</b>) by Cu-catalyzed reaction with methanesulfinic acid sodium salt in DMSO.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Aryl hydrazines were obtained by reducing diazonium salts with SnCl<sub>2</sub> (procedure C, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) or introducing the hydrazine moiety to heteroaryl bromide derivatives by Pd-catalyzed coupling reaction of di-<i>tert</i>-butyl hydrazodiformate (BocNHNHBoc) as a hydrazine source (procedure D, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The aryl hydrazines, especially heteroaryl hydrazines, were unstable in air. The aryl hydrazines were each isolated as a salt of hydrochloric acid and subjected to the aminopyrazole formation steps using in situ neutralization protocols with a neutralizing reagent (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Aminopyrazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LHMDS, MeCN, THF −78 °C; (b) DMF-DMA; (c) Ar<sup>2</sup>NHNH<sub>2</sub> HCl, 100 °C.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Indole Aminopyrazole Derivatives (<b>4</b>–<b>15</b> and <b>17</b>–<b>19</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, ArylSO<sub>2</sub>Cl, THF; (b) LHMDS, MeCN, THF −78 °C; (c) DMF-DMA; (d) Ar<sup>2</sup>NHNH<sub>2</sub> HCl, 100 °C.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LHMDS, MeCN, THF −78 °C; (b) DMF-DMA, THF; (c) ArNHNH<sub>2</sub> HCl, 100 °C; (d) sodium methanesulfinate, CuI, <i>N</i>1,<i>N</i>2-dimethylcyclohexane-1,2-diamine, DMSO, 120 °C.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of aryl Hydrazines (<b>7a</b>, <b>9c</b>, <b>10c</b>, <b>11c</b>, and <b>12a</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>, Pd-C, H<sub>2</sub>O-EtOH; (b) NaNO<sub>2</sub>, dil. HCl then SnCl<sub>2</sub>, 0 °C; (c) Pd<sub>2</sub>dba<sub>3</sub>, <i>t</i>-Bu XPhos, BocNHNHBoc, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C; (d) 4 M HCl-AcOEt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Molecular Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10353" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10353" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to obtain an FGFR-selective inhibitor, we performed a high-throughput screening against our chemical library and identified a screening hit (<b>1</b>) (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) that inhibited a relatively broad range of kinases but had a different chemical scaffold from the other known FGFR inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The chemical modifications strategy guided by 3D modeling of inhibitors and FGFR1 is outlined in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. A 3D model structure of <b>1</b> and FGFR1 suggested that compound <b>1</b> was located in the ATP-binding site of FGFR1 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Analysis of the 3D modeling structure also suggested an interaction of the amino group and the carbonyl group of <b>1</b> with the backbone of the hinge region (E562 and A564) of FGFR1. Additionally, the phenolic hydroxyl group of <b>1</b> was supposed to interact with D641 through a hydrogen bond in the backpocket region of FGFR1. In addition to these interactions, we assumed that a further functional group could be introduced to <b>1</b> to gain additional interaction with FGFRs. In <b>1</b>, an <i>m</i>-tolyl group was located near the tyrosine residue (Y563) in the hinge region, and replacing the <i>m</i>-tolyl moiety was expected to strengthen the π–π interaction between Y563 and the inhibitors. Addition of a hydrogen donor to <b>1</b> in the direction of the carbonyl group of A564 was predicted to enhance the interaction at the hinge region of FGFRs. Replacement of the phenol moiety by an isostere of phenol was considered to be essential to avoid metabolic instability. We envisioned that we could improve the specificity to FGFRs by implementing either a favorable interaction between the inhibitor and amino acid residues common in FGFRs or an unfavorable interaction between the inhibitor and amino acid residues in off-target kinases. Interaction of inhibitors with both the methionine residue (M535 in FGFR1) and the valine residue (V561 in FGFR1) could improve both kinase inhibitory activity and specificity to FGFRs (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Introducing a solubilizing group at the <i>m</i>-tolyl moiety was considered to be beneficial if the solubility of the inhibitors was insufficient.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure analysis of 3D modeling of <b>1</b> (magenta) and FGFR1. The side chains of amino acid residues important for ligand recognition of FGFR1 are highlighted as sticks (green). Hydrogen bonds at hinge region and backpocket region are indicated in blue dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Amino Acid Sequences of FGFR1, KDR, and SRC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0011.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p">To confirm the selective antitumor efficacy of the inhibitors, we tested them in a kinase inhibitory assay and an in vitro antiproliferative activity assay. Because compound <b>1</b> inhibited a relatively broad range of kinases such as KDR and proto-oncogene (SRC) which were considered to potentially be off-target kinases, the inhibitory activity against FGFRs, KDR, and SRC was measured in a cell-free system to evaluate selectivity of kinase inhibition.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The sequence identity between FGFR1 and FGFR2 at the kinase domain was 87.6%, and the pivotal interactions between <b>1</b> and the amino acid residues of FGFR1 were expected to agree with those of FGFR2. Because the inhibitors had the same binding mode with FGFR1 and FGFR2, the inhibitory activity against FGFR1 correlated well with that against FGFR2. We concluded that the antiproliferative activity of the inhibitors in SNU-16 (gastric cancer, <i>FGFR2</i> amplification) was appropriate for the in vitro assay, even though the 3D modeling of the inhibitors was performed in FGFR1. The antiproliferative activity against HCT116 (colorectal cancer, WT FGFR) was evaluated as a negative control cell lines.</div><div class="NLM_p last">As an entry to the lead optimization process, we prepared a series of compounds bearing an aminopyrazole scaffold to explore their structure–activity relationships (SARs) by replacing the <i>m</i>-tolyl group in the solvent-exposed region of <b>1</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Hit-to-Lead</h3><div class="NLM_p">The <i>m</i>-tolyl group was replaced into bicyclic aromatics in order to direct the aromatic ring of inhibitors in the solvent-exposed region near Y563 in FGFR1. As we expected, the bicyclic compounds <b>2</b> and <b>3</b> showed better kinase inhibitory activity than the monocyclic compound (<b>1</b>) because the π–π interaction between Y563 of FGFR1 and inhibitors was enhanced (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Interestingly, compound <b>4</b> showed the most potent kinase inhibitory activity out of the bicyclic compounds. The 3D modeling analysis of <b>4</b> with FGFR1 suggested that the phenyl moiety of the indole was forced into parallel geometry with Y563, and the hydrogen of the NH in the indole additionally interacted with the backbone of A564. We concluded that the indole was the optimal bicyclic heteroaromatic and explored modification of the backpocket region and the solvent-exposed region in next step, using <b>4</b> as the lead compound.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Hit-to-Lead</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0012.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Compared with the lead compound (<b>4</b>), a drop in inhibitory activity of 1 order of magnitude was observed in <b>5</b> by removing the phenolic hydroxyl group in <b>4</b>. The hydroxyl group in <b>4</b> probably interacted with the carboxylic acid at D641 in FGFR1 by a hydrogen bond. This interaction was supposed to be essential to keep the inhibitory activity against FGFRs, because the aspartic acids corresponding to D641 in FGFR1 were well conserved in FGFRs. On the other hand, the aspartic acids corresponding to D641 in FGFR1 were also conserved in several kinases including KDR and SRC (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). As described earlier, the inhibition of KDR is known to induce hypertension. We were also concerned about inhibition of SRC which is reported to lead to osteopetrosis in animal study.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In addition to the interaction between inhibitors and kinases, a phenolic hydroxyl group was generally known to form a conjugate metabolite. To avoid both a broad kinase inhibition spectrum and drug metabolism, it was necessary to replace the phenol to its isostere. We analyzed the 3D structure of the backpocket region and the hinge region and hypothesized that compounds in FGFR1 interacting with M535, V559, and V561, which are the commonly conserved amino acid residues in FGFRs, could improve the specificity to FGFRs over SRC and KDR (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). The discrimination between FGFR1 and SRC would be considered to be due to the different characteristic of V561 (in FGFR1) versus T341 (in SRC) and of V559 (in FGFR1) versus I339 (in SRC)(<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Though the only amino acid residues that were different at the ATP-binding site in FGFR1 and KDR were M535 (FGFR1) and L889 (KDR), a steric repulsion between the inhibitors and L889 (KDR) could be expected at this site (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). When a solubilizing group was introduced in the solvent-exposed indole moiety of <b>4</b>, the kinase inhibitory activity of <b>6</b> was improved (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). On the other hand, the selectivity to FGFRs over SRC and KDR was insufficient due to the high sequence similarity of FGFRs, SCR, and KDR at the solvent-exposed regions. Thus, we tried to modify the backpocket region to improve the specificity to FGFRs.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A, B) Neighboring amino acid residues of FGFR1 (green), KDR (magenta), and SRC (cyan) around <b>4</b> (orange). The binding models were created by overlapping X-ray structures of FGFR1 (2FGI), KDR (3WZD), and SRC (3G5D). (C, D) Superimposed structures of <b>4</b> (purple) and <b>8</b> (green) in FGFR1. The hydrogen bonds between <b>8</b> and FGFR1 (E531 and D641) are indicated in blue dotted lines. The benzimidazole in <b>8</b> interacts better with V561, I545, and F641 by CH−π interaction (orange dotted lines) than phenoxy group in <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Modification of the Backpocket Region</h3><div class="NLM_p">By analyzing a 3D structure of the backpocket region of FGFR1, we designed several bicyclic heteroaromatics with a hydrogen donor that could form a hydrogen bond to D641 to fit the cavity formed by E531, M535, V561, A640, and D641 in the binding pocket (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> and <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). A screening of the heteroaromatics revealed that the benzimidazole derivatives (<b>7</b>, <b>8</b>, and <b>9</b>) showed greater specificity to FGFRs than the low specificity to FGFRs of indole derivatives (<b>10</b> and <b>11</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). According to 3D modeling of <b>10</b> and <b>11</b> with FGFR1, the indole derivatives (<b>10</b> and <b>11</b>) still showed inhibitory activity against FGFRs probably due to the hydrogen bond between the NH group of indole and E531 in FGFRs. Interestingly, compound <b>11</b> showed better inhibitory activity against FGFRs than <b>10</b> probably because of CH−π interaction between the 2-methyl group of the indole in <b>11</b> and F642 in FGFR1, but the specificity of these indole derivatives to FGFRs needed to be improved to avoid the potential risk of drug related toxicity from having a broad spectrum of kinase inhibition.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR in Modification of Backpocket Region<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">N.T.: Not tested.</p></div></div><div></div></div><div class="NLM_p">We explored the 2-position of the benzimidazole of <b>7</b>, and it was revealed that 2-methyl-benzimidazole derivative (<b>8</b>) was optimal in terms of kinase selectivity. In addition to kinase selectivity, the profiles of <b>8</b> were well balanced in terms of in vitro cellular antiproliferative activity against SNU-16 and stability in human liver microsome. While the 2-ethyl benzimidazole derivative (<b>9</b>) showed equivalent kinase inhibition and cellular growth inhibition profiles as <b>8</b>, its stability in human liver microsome did not meet our criteria (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The low kinase inhibitory activity of the benzimidazolinone derivative (<b>12</b>) against all the tested kinases suggested the importance of both the hydrogen acceptor and the hydrogen donor of the benzimidazole group. We speculated that the nitrogen of the benzimidazole group of <b>8</b> formed a hydrogen bond with the backbone of A640, and the NH group of the benzimidazole formed another hydrogen bond with the side chain of E531. In addition to these hydrogen bonds, the benzimidazole ring was located in the hydrophobic pocket formed by M535, V561, and F642, according to an X-ray structure of the binary complex of <b>8</b> and FGFR1 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Furthermore, an S−π interaction between the sulfur atom of M535 and the benzimidazole ring was suggested.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Solubility in FaSSIF and Stability (CL<sub>int</sub>) in Human Liver Microsome</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (μL/min/mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr></tbody></table></div></div><div class="NLM_p last">The selectivity of <b>8</b> to inhibit FGFR over KDR was suggested to be caused by the difference in the interaction with M535 in FGFR1 and L889 in KDR, because the leucine residue in KDR would disrupt the formation of the S−π interaction with the benzimidazole moiety of <b>8</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). The selectivity to FGFR over SRC was also suggested to be the result of a disruption of a crucial interaction between <b>8</b> and the lipophilic binding pocket formed by V561 and V559 in FGFR1, which were T314 and I339 in SRC (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). On the other hand, compound <b>4</b> showed a broad kinase inhibitory activity against the tested kinases because the chloro-phenyl moiety of <b>4</b> had effective interactions with amino acid residues other than those in FGFR1. The 3D modeling of <b>4</b> and <b>8</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D) suggested that the chloro-phenyl ring of <b>4</b> and the benzimidazole ring of <b>8</b> had different geometry, and the chloro-phenyl moiety of <b>4</b> had no repulsive interaction against either FGFR1, KDR, or SRC (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,B). Furthermore, the benzimidazole derivatives were much soluble in fasted state simulated intestinal fluid (FaSSIF) than indole derivatives (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). As described above, we concluded that the 2-methyl-benzimidazole group was optimal in the backpocket region of an inhibitor and planned to modify the solvent-exposed region of compounds that had 2-methyl-benzimidazole group in 1-position of the aminopyrazole.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Modification of the Solvent-Exposed Region to Reduce Cardiovascular Effects</h3><div class="NLM_p">In spite of <b>8</b>’s high specificity to FGFRs, an inhibition of cardiac K<sup>+</sup> channel encoded by the human <i>ether-a-go-go-related</i> gene (hERG) (IC<sub>50</sub> 6.9 μM, 69% inhibition at 10 μM, <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>) was observed in an early safety study.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition to hERG inhibition, the inhibitory activity of <b>8</b> on KDR (IC<sub>50</sub> 2.1 μM) was also suggested to cause hypertension. Cardiovascular side effects, especially QTc prolongation, are associated with inhibition of the hERG channel, which has resulted in several drugs being withdrawn from the market and which is still one of the potential risks in the R&D process of new molecular entities.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As we mentioned above, hypertension (grades 3 and 4) caused by inhibiting KDR was reported to be the dose-limiting toxicity of KDR inhibitors in clinical trials. We hypothesized that modifying the solvent-exposed region of <b>8</b> might improve the hERG inhibition without losing the inhibitory activity against FGFRs. Both lipophilic and hydrophilic functionalities were introduced to <b>8</b> to reduce hERG inhibition by controlling log <i>P</i>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">First, amino groups with low p<i>K</i><sub>a</sub>, such as morpholine or 4-difluoropiperidine, were introduced at the 5- or 6-position of indole in <b>8</b>. The inhibitory activities against FGFRs and SNU-16 were maintained by introducing amino groups (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Because introducing an electronegative oxygen at β-position or an electron-withdrawing fluorine atom at γ-position of basic nitrogen reduced the p<i>K</i><sub>a</sub> value of amino groups, the reduction of the hERG binding affinity by lowering the basicity of nitrogen in amino groups was expected.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The p<i>K</i><sub>a</sub> value of nitrogen of morpholine in <b>13</b> and <b>14</b> was reduced from 9.23 (piperidine) to 7.11 (<b>13</b>) and 7.24 (<b>14</b>) by replacing piperidine to morpholine, and the p<i>K</i><sub>a</sub> value of nitrogen in 4-difluoropiperidine derivative (<b>15</b>) was also reduced to 6.39 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The strategy to reduce inhibition of hERG by polar groups worked well in <b>13</b> and <b>14</b>, but not in <b>15</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). The solubility of these amino derivatives (<b>13</b>, <b>14</b>, and <b>15</b>) was improved by introducing hydrophilic groups, but the permeability in a Caco2 study was reduced, compared to <b>8</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). The low permeability of these compounds resulted in low oral bioavailability (BA) in a monkey pharmacokinetic (PK) study (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Next, lipophilic groups were introduced in the 6-position of indole, and the in vitro profiles are summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. The 6-bromo-indole derivative (<b>17</b>) and the 6-methyl-indole derivative (<b>18</b>) showed better permeability in the Caco2 study among lipophilic derivatives, and compound <b>17</b> exhibited 20% BA in the monkey PK study (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Unfortunately, a weaker inhibition of hERG was observed in <b>17</b> than <b>8</b>, but another cardiovascular side-effect was suggested by a safety study (data not shown). The 6-phenyl-indole derivative (<b>19</b>) showed the same in vitro properties as <b>8</b> and a weak hERG inhibition, but the BA of <b>19</b> was low (3% in monkey). We concluded that oral BA could be predicted by the permeability in Caco2 and that hERG inhibition and oral BA could not be improved at the same time by modifying the solvent-exposed region.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. p<i>K</i><sub>a</sub> values of amines in the solvent exposed region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR in Optimization of Solvent Exposed Region</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0016.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Physicochemical Properties, Suppression of hERG, and BA in Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (μL/min/mg) Human</th><th class="colsep0 rowsep0" align="center" char=".">Caco2 (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hERG % inhibition @10 μM</th><th class="colsep0 rowsep0" align="center" char=".">monkey BA (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">N.T.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">0.075</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">N.T.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">2.2<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">N.T.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">0.070</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Caco2 assay at 100 μM except for <b>17</b> (10 μM). N.T.: Not tested.</p></div></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Assessment of Cardiovascular Effect of <b>8</b></h3><div class="NLM_p last">We tried to evaluate the profiles of <b>8</b> in detail, because there was some concern around possible cardiovascular risk due to inhibitory activity against KDR and hERG inhibition as described earlier. We examined a safety assessment study to evaluate a potential risk of cardiovascular effect of <b>8</b>. Compound <b>8</b> did not lead to either QTc prolongation in Langendorff’s isolated heart perfusion model in guinea pig or to significant changes in blood pressure compared with vehicle-dosed rats and monkeys (data not shown). The effect of <b>8</b> on blood pressure in telemetry-instrumented rats at a dose of 30 mg/kg did not lead to significant changes in blood pressure compared with vehicle-dosed animals.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Of note, the plasma exposure of <b>8</b> in rats (AUC: 102 μg·h·mL<sup>–1</sup>) at a dose of 30 mg/kg was 4-fold higher than the exposure inducing a >100% tumor growth inhibition in the SNU-16 mouse xenograft model (AUC: 26 μg·h·mL<sup>–1</sup> at a dose of 30 mg/kg).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Therefore, compound <b>8</b> was predicted to have no biologically significant effect on blood pressure at multiples of the efficacious dose.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Efficacy in Tumor Xenograft Studies</h3><div class="NLM_p last">The in vivo efficacy was evaluated in mice bearing an SNU-16 xenograft. Compound <b>8</b> was orally administered once daily for 11 days, and the body weight of mice and the volume of the tumors were measured twice a week. A dose-dependent tumor regression (tumor growth inhibition (TGI) = 106% at 30 mg/kg and 147% at 100 mg/kg) was observed without apparent body weight loss.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compound <b>8</b> also showed significant in vivo efficacy in xenograft mice models with <i>FGFR</i> genetic alterations, such as KG1 (leukemia, <i>FGFR1OP-FGFR1</i> fusion), MFE280 (endometrial cancer, <i>FGFR2</i> S252W mutation), UM-UC-14 (bladder cancer, <i>FGFR3</i> S249C mutation), and RT112/84 (bladder cancer, <i>FGFR3-TACC3</i> fusion).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These results suggested <b>8</b>’s therapeutic potential of cancers harboring <i>FGFR</i> genetic alterations.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We identified <b>8</b> as a potent and selective FGFR inhibitor with a novel chemical scaffold by exploiting crystallographic structure information on FGFRs with their inhibitors. Compound <b>8</b> only bound to five kinases, including FGFR1, FGFR2, and FGFR3, out of 442 WT and mutant kinases at 100 nM in KINOMEscan panel (DiscoveRx).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The benzimidazole moiety of <b>8</b> was located at the backpocket region of FGFR1 according to the X-ray crystal structure of binary complex of FGFR1 and <b>8</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). The recognition of the different amino acid residues in FGFRs, KDR, and SRC was achieved by introducing 2-methyl-benzimidazole in the backpocket region of <b>8</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). The benzimidazole moiety was positioned in the same region of FGFR1 as the 3,5-dimethoxy-phenyl groups in <b>21</b> and <b>22</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). It may be possible to overcome acquired resistance, such as a gatekeeper mutation, because the binding mode of <b>8</b> is different from that of <b>21</b> and <b>22</b> at both the backpocket region and the hinge region of FGFR1.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> A preclinical PK evaluation in mice, rats, and monkeys revealed that the compound was orally bioavailable in both rodents and nonrodents. When the anticancer efficacy was evaluated, compound <b>8</b> potently inhibited the proliferation of gastric cancer cell lines with amplified FGFR2 and exhibited dose-dependent antitumor efficacy in SNU-16 xenograft models. Compound <b>8</b> will provide therapeutic opportunities for patients who have <i>FGFR</i> genetic alterations and patients with acquired resistance to existing FGFR-selective inhibitors.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. 3D structures of <b>8</b>, <b>21</b>, and <b>22</b>. (A) The X-ray crystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>) of <b>8</b> (purple) and FGFR1. The side chains of the amino acid residues important for ligand recognition of FGFR1 are highlighted as sticks (green). Hydrogen bonds are indicated in blue dotted lines. The CH−π and S−π interactions are indicated in orange dotted lines. (B) The overlapped structure of <b>8</b> (green), FGFR1 (green), KDR (magenta), and SRC (light blue). The side chains of the amino acid residues around <b>8</b> in the backpocket regions are reported as sticks. (C) The overlapped structure of <b>8</b> (magenta), <b>21</b> (light blue), and <b>22</b> (green) in FGFR1. The side chains of the amino acid residues around <b>8</b>, <b>21</b>, and <b>22</b> in the backpocket regions are reported as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Synthetic and Analytical Chemistry Methods</h3><div class="NLM_p last">All reagents and solvents were purchased from commercial sources and used as received. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a JEOL JNM-ECA400 (400 MHz), a Varian MR400 (400 MHz), a Bruker AVANCE III HD600 (600 MHz), or a Bruker AVANCE III 600 Cryo-TCI (600 MHz). The chemical shifts are expressed as δ units using tetramethylsilane as an internal standard. The following abbreviations are used: singlet (s), doublet (d), double doublets (dd), triplet (t), quartet (q), multiplet (m), broad peak (br), and broad singlet (brs). LC-MS analyses were performed on a Waters Micromass SQD instrument coupled to a Waters Acuity UPLC and PDA instruments. Analytical reverse-phase ultra-high-performance liquid chromatography (UPLC) experiment was carried out on an Ascentis Express C<sub>18</sub> column (2.1 × 50 mm, 2.7 μm) or Acquity UPLC BEH Phenyl column (2.1 × 50 mm, 1.7 μm). Eluents in UPLC used were solvent A (H<sub>2</sub>O with 0.1% formic acid) and solvent B (MeCN with 0.1% formic acid) or solvent C (H<sub>2</sub>O with 0.03% TFA) and solvent D (MeCN with 0.03% TFA) and eluted by a linear gradient at 1.0 mL/min. High-resolution mass spectra (HRMS) were measured with a Xevo G2-SL (Waters) MS spectrometer using an ESI source coupled to a Waters HPLC system operating in reversed phase with an ACQUITY UPLC BEH C<sub>18</sub> column (2.1 × 50 mm, 1.7 μm). Normal phase and reverse-phase flash column chromatography were performed with Biotage SNAP cartridges equipped with SP1 or Isolera One (Biotage). The purities of all tested compounds are >95%. The purity was determined by LC-MS analysis.</div></div><div id="sec6_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure A for Synthesis of the Aminopyrazole Compounds <b>1</b>–<b>3</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h3><div id="sec6_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> [5-Amino-1-(2-chloro-5-hydroxy-phenyl)pyrazol-4-yl]-(<i>m</i>-tolyl)methanone (<b>1</b>)</h4><div class="NLM_p">(<i>E</i>)-3-(Dimethylamino)-2-(3-methylbenzoyl)prop-2-enenitrile (<b>1a</b>, 107 mg, 0.500 mmol) and 4-chloro-3-hydrazino-phenol hydrochloride (146 mg, 0.750 mmol) were placed in a screw-capped vial, and then EtOH (1.0 mL) was added to the vial. Nitrogen gas was bubbled into the reaction mixture, and then the mixture was stirred at 78 °C for 10 h under nitrogen atmosphere. The solution was diluted with DMSO (2 mL) and then subjected to a C<sub>18</sub> medium-pressure liquid chromatography (MPLC) column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected and then concentrated under reduced pressure to give the titled compound as a light yellow powder (26 mg, 15%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.13 (1H, s), 7.76 (1H, s), 7.56–7.54 (2H, m), 7.46 (1H, d, <i>J</i> = 8.8 Hz), 7.41–7.39 (2H, m), 7.04 (2H, s), 6.96 (1H, dd, <i>J</i> = 8.8, 2.7 Hz), 6.87 (1H, d, <i>J</i> = 2.7 Hz), 2.40 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 187.74, 157.14, 152.15, 141.40, 139.71, 137.89, 134.79, 131.84, 130.90, 128.42, 128.31, 125.07, 120.75, 118.36, 116.64, 102.50, 20.97. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 328.0853, found: 328.0852.</div></div><div id="sec6_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> [5-Amino-1-(2-chloro-5-hydroxy-phenyl)pyrazol-4-yl]-(benzofuran-2-yl)methanone (<b>2</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_1" aria-label="general procedure A">general procedure A</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.20 (1H, s), 8.47 (1H, s), 7.83 (1H, dd, <i>J</i> = 2.7, 1.1 Hz), 7.81 (1H, dd, <i>J</i> = 3.3, 1.1 Hz), 7.77 (1H, d, <i>J</i> = 1.1 Hz), 7.55–7.51 (1H, m), 7.49 (1H, d, <i>J</i> = 8.8 Hz), 7.38 (1H, td, <i>J</i> = 7.7, 0.9 Hz), 7.21 (2H, s), 6.99 (1H, dd, <i>J</i> = 8.8, 2.7 Hz), 6.92 (1H, d, <i>J</i> = 2.7 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 174.34, 157.12, 154.75, 153.52, 152.64, 140.87, 134.63, 130.92, 127.43, 126.94, 123.86, 123.03, 120.84, 118.43, 116.69, 112.34, 111.38, 101.95. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 354.0645, found: 354.0645.</div></div><div id="sec6_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> [5-Amino-1-(2-chloro-5-hydroxy-phenyl)pyrazol-4-yl]-(6-quinolyl)methanone (<b>3</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_1" aria-label="general procedure A">general procedure A</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.93 (1H, s), 8.47 (1H, dd, <i>J</i> = 4.4, 1.6 Hz), 8.39 (1H, s), 7.86 (1H, d, <i>J</i> = 8.2 Hz), 7.63 (1H, br s), 7.55 (1H, s), 7.30 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.26 (1H, dd, <i>J</i> = 8.2, 4.4 Hz), 7.09 (2H, s), 2.54 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 186.73, 157.12, 152.31, 152.10, 148.68, 141.62, 137.54, 137.13, 134.77, 130.93, 129.36, 128.72, 128.33, 127.29, 122.13, 120.82, 118.40, 116.65, 102.64. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 365.0805, found: 365.0795.</div></div></div><div id="sec6_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure B for Synthesis of the Aminopyrazole Compounds <b>4</b>–<b>7</b>, <b>9</b>–<b>15</b>, and <b>17</b>–<b>19</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h3><div id="sec6_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> [5-Amino-1-(2-chloro-5-hydroxy-phenyl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>4</b>)</h4><div class="NLM_p">(<i>E</i>)-3-(Dimethylamino)-2-[1-(<i>p</i>-tolylsulfonyl)indole-2-carbonyl]prop-2-enenitrile (<b>4c</b>, 100 mg, 0.254 mmol) and 4-chloro-3-hydrazino-phenol hydrochloride (74.4 mg, 0.381 mmol) were placed in a screw-capped vial, and then NMP (1.0 mL) was added to the vial. 4-Methylmorpholine (0.042 mL, 0.381 mmol) was added to the solution, and then nitrogen gas was bubbled into the reaction mixture. The mixture was stirred at 100 °C for 1 h under nitrogen atmosphere. Five M NaOH (0.250 mL) was added to the solution, and then the mixture was stirred at 100 °C for 2 h under nitrogen atmosphere. The reaction mixture was subjected to a C<sub>18</sub> MPLC column, and then the column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected. The eluent was passed through MP-CO3 cartridges (Biotage, one cartridge (3 g) per 36 mL of fraction) to remove formic acid. The resulting solution was concentrated under reduced pressure to give the titled compound as a light yellow amorphous (47 mg, 52%).</div><div class="NLM_p last"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.67 (1H, s), 10.17 (1H, s), 8.30 (1H, s),7.69 (1H, d, <i>J</i> = 8.1 Hz), 7.49–7.48 (2H, m), 7.44 (1H, d, <i>J</i> = 1.5 Hz), 7.26–7.23 (1H, m), 7.09–7.06 (1H, m), 7.02 (2H, s), 6.98 (1H, dd, <i>J</i> = 8.8, 2.9 Hz), 6.90 (1H, d, <i>J</i> = 2.9 Hz); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.75, 156.99, 152.09, 140.16, 136.73, 135.41, 134.73, 130.79, 127.39, 124.23, 122.14, 120.70, 119.81, 118.23, 116.57, 112.37, 106.28, 102.04. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 353.0805, found: 353.0810.</div></div><div id="sec6_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> [5-Amino-1-(2-chlorophenyl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>5</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.70 (1H, s), 8.34 (1H, s), 7.74–7.73 (1H, m), 7.69 (1H, d, <i>J</i> = 7.5 Hz), 7.63–7.53 (3H, m), 7.49 (1H, dd, <i>J</i> = 8.4, 0.9 Hz), 7.46 (1H, d, <i>J</i> = 1.3 Hz), 7.27–7.23 (1H, m), 7.09–7.07 (3H, m); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.76, 152.31, 140.29, 136.73, 135.39, 134.40, 131.67, 131.27, 130.36, 130.31, 128.35, 127.39, 124.25, 122.15, 119.82, 112.37, 106.30, 102.07. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 337.0856, found: 337.0852.</div></div><div id="sec6_1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> [5-Amino-1-(2-chloro-5-hydroxy-phenyl)pyrazol-4-yl]-[5-(morpholinomethyl)-1<i>H</i>-indol-2-yl]methanone (<b>6</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.66 (1H, s), 8.29 (1H, s), 7.57 (1H, s), 7.50–7.46 (2H, m), 7.41 (2H, d, <i>J</i> = 2.2 Hz), 7.22 (1H, dd, <i>J</i> = 8.4, 1.3 Hz), 7.03 (2H, s), 6.98 (1H, dd, <i>J</i> = 8.8, 3.1 Hz), 6.90 (1H, d, <i>J</i> = 3.1 Hz), 3.57 (4H, t, <i>J</i> = 4.4 Hz), 3.52 (2H, s), 2.37 (4H, br s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.72, 157.07, 152.06, 140.18, 136.11, 135.62, 134.71, 130.78, 129.12, 129.04, 128.33, 127.27, 122.26, 120.63, 116.59, 112.12, 106.19, 102.03, 66.12 (2C), 62.92, 53.09 (2C). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 452.1489, found: 452.1492.</div></div><div id="sec6_1_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3<i>H</i>-Benzimidazol-5-ylhydrazine dihydrochloride (<b>7a</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_3" aria-label="general procedure C">general procedure C</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.63 (3H, br s), 9.47 (1H, s), 8.73 (1H, s), 7.77 (1H, d, <i>J</i> = 8.8 Hz), 7.39 (1H, s), 7.23 (1H, d, <i>J</i> = 8.8 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 144.96, 140.10, 131.68, 125.81, 115.73, 115.51, 98.09. MS (ESI): <i>m</i>/<i>z</i> 149 [M + H]<sup>+</sup>.</div></div><div id="sec6_1_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> [5-Amino-1-(3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>7</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.74 (1H, s), 8.46 (1H, s), 8.36 (1H, s), 7.82–7.81 (1H, m), 7.79 (1H, s), 7.71 (1H, d, <i>J</i> = 7.7 Hz), 7.53–7.50 (1H, m), 7.48 (1H, d, <i>J</i> = 1.1 Hz), 7.44 (1H, dd, <i>J</i> = 8.2, 2.2 Hz), 7.27 (1H, td, <i>J</i> = 7.7, 1.1 Hz), 7.13–7.09 (3H, m); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.15, 151.32, 143.71, 140.08, 136.89, 135.58, 131.91, 128.12, 127.52, 125.53, 124.42, 122.30, 119.98, 119.25, 115.97, 112.51, 111.69, 106.55, 103.18. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>14</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 343.1307, found: 343.1311.</div></div><div id="sec6_1_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>8</b>)</h4><div class="NLM_p">(<i>E</i>)-3-(Dimethylamino)-2-[1-(<i>p</i>-tolylsulfonyl)indole-2-carbonyl]prop-2-enenitrile (<b>4c</b>, 79 mg, 0.200 mmol) and (2-methyl-3<i>H</i>-benzimidazol-5-yl)hydrazine dihydrochloride (56 mg, 0.240 mmol) were placed in a round-bottomed flask, and then EtOH (2.0 mL) was added thereto. The mixture was stirred at 80 °C for 2 h under nitrogen atmosphere. The mixture was cooled to 25 °C, and then the precipitate was collected by filtration. The cake was washed with H<sub>2</sub>O (2 mL). The powder was dried under reduced pressure. The powder was suspended in EtOH (17 mL), and then 4 M NaOH (1.7 mL) was added to the suspension. The mixture was stirred at 25 °C for 4 h under nitrogen atmosphere. The volatile was removed under reduced pressure to 5 mL. H<sub>2</sub>O (5 mL), and 4 M HCl (1.7 mL) was added to the mixture at 0 °C. The precipitate was collected by filtration. The cake was washed with H<sub>2</sub>O (2 mL). The powder was dried under reduced pressure to give the titled compound as a light yellow powder (58 mg, 81%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (1H, s), 8.36 (1H, s), 7.80 (1H, d, <i>J</i> = 1.6 Hz), 7.77 (1H, d, <i>J</i> = 8.8 Hz), 7.70 (1H, d, <i>J</i> = 8.2 Hz), 7.49 (3H, td, <i>J</i> = 8.7, 1.6 Hz), 7.26 (1H, t, <i>J</i> = 7.7 Hz), 7.14 (2H, s), 7.09 (1H, t, <i>J</i> = 7.7 Hz), 2.69 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.11, 153.06, 151.32, 140.27, 136.88, 135.62, 135.51, 134.78, 132.58, 127.48, 124.43, 122.28, 119.97, 119.84, 114.62, 112.50, 110.31, 106.57, 103.19, 13.74. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>16</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 357.1464, found: 357.1475.</div></div></div><div id="sec6_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure C for Synthesis of the Aryl Hydrazines <b>9c</b>, <b>7a</b>, and <b>12a</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>)</h3><div id="sec6_1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-Ethyl-6-nitro-1<i>H</i>-benzimidazole (<b>9a</b>)</h4><div class="NLM_p">4-Nitrobenzene-1,2-diamine (766 mg, 5.00 mmol) was suspended in MeCN (7.6 mL), and then <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (1.31 mL, 7.50 mmol) was added to the suspension. Propionyl chloride (0.524 mL, 6.00 mmol) was added to the suspension with ice-cooling keeping the inner temperature of the reaction mixture below 25 °C. The mixture was stirred at 25 °C for 1 h under nitrogen atmosphere. H<sub>2</sub>O (15 mL) was added to the solution at 25 °C, and then the precipitate was collected by filtration. The cake was washed with H<sub>2</sub>O/methanol (MeOH) (2/1, 5.0 mL). The powder was dried under reduced pressure. The powder was suspended in MeOH (7.0 mL), and then concentrated HCl (2.1 mL) was added to the suspension. The mixture was stirred at 70 °C for 1 h. Five M NaOH (5.0 mL) was added to the suspension, and then the precipitate was collected by filtration. The powder was dissolved in DMSO (2.0 mL), and then the solution was subjected to a C<sub>18</sub> MPLC column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected and concentrated under reduced pressure to give the titled compound as a light brown powder (343 mg, 35%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.90 (1H, s), 8.38 (1H, d, <i>J</i> = 1.6 Hz), 8.07 (1H, dd, <i>J</i> = 8.8, 2.2 Hz), 7.65 (1H, d, <i>J</i> = 8.8 Hz), 2.91 (2H, q, <i>J</i> = 7.6 Hz), 1.35 (3H, t, <i>J</i> = 7.6 Hz). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>9</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 192.0773, found: 192.0772.</div></div><div id="sec6_1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Ethyl-3<i>H</i>-benzimidazol-5-amine hydrochloride (<b>9b</b>)</h4><div class="NLM_p">2-Ethyl-6-nitro-1<i>H</i>-benzimidazole (<b>9a</b>, 200 mg, 1.05 mmol) was dissolved in EtOH (2.0 mL), and then 5 M HCl (0.50 mL) and Pd–C (50.0 mg) suspended in H<sub>2</sub>O (0.50 mL) were added to the solution. The mixture was stirred at 25 °C for 3 h under hydrogen atmosphere. The catalyst was removed by filtration, and then the filter paper was washed with EtOH (4 mL). The filtrate was concentrated under reduced pressure to give the titled compound as a light yellow powder (241 mg, 100%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.21 (4H, br s), 7.81 (1H, d, <i>J</i> = 8.8 Hz), 7.73 (1H, s), 7.43–7.42 (1H, m), 3.16 (2H, q, <i>J</i> = 7.5 Hz), 1.44 (3H, t, <i>J</i> = 7.7 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 156.08, 132.10, 131.05, 128.71, 119.72, 114.58, 106.50, 19.85, 10.68. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>9</sub>H<sub>11</sub>N<sub>3</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 162.1031, found: 162.1033.</div></div><div id="sec6_1_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2-Ethyl-3<i>H</i>-benzimidazol-5-yl)hydrazine dihydrochloride (<b>9c</b>)</h4><div class="NLM_p">NaNO<sub>2</sub> (101 mg, 1.46 mmol) in H<sub>2</sub>O (0.25 mL) was added to the suspension of 2-ethyl-3<i>H</i>-benzimidazol-5-amine hydrochloride (<b>9b</b>, 241 mg, 1.22 mmol) in diluted HCl (concentrated HCl/H<sub>2</sub>O: 1 mL/0.25 mL) at 0 °C over 5 min. SnCl<sub>2</sub>·2H<sub>2</sub>O (605 mg, 2.68 mmol) in concentrated HCl (2.23 mL) was added to the resulting solution at 0 °C over 5 min. The resulting mixture was stirred at 0 °C for 30 min. The solution was charged onto SCX cartridges (5 g × 3), and then the cartridges were eluted with MeOH (10 mL each). The cartridges were eluted with 2 M NH<sub>3</sub> MeOH (10 mL each), and then the eluent was evaporated off with 5 M HCl (15 mL). The residue was dissolved in H<sub>2</sub>O (5 mL), and then the solution was subjected to a C<sub>18</sub> MPLC column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected and concentrated with 5 M HCl (2 mL) under reduced pressure to give the titled compound as a colorless powder (183 mg, 60%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.66 (1H, d, <i>J</i> = 8.8 Hz), 7.40 (1H, d, <i>J</i> = 1.8 Hz), 7.18 (1H, dd, <i>J</i> = 9.0, 2.0 Hz), 3.12 (2H, q, <i>J</i> = 7.6 Hz), 1.42 (3H, t, <i>J</i> = 7.7 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 154.49, 143.97, 131.24, 125.38, 114.29, 114.04, 97.54, 19.68, 10.83. MS (ESI): <i>m</i>/<i>z</i> 177 [M + H]<sup>+</sup>.</div></div><div id="sec6_1_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> [5-Amino-1-(2-ethyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>9</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.72 (1H, s), 8.33 (1H, s), 8.15 (1H, s), 7.70 (1H, d, <i>J</i> = 8.2 Hz), 7.64 (1H, s), 7.62 (1H, s), 7.50 (1H, d, <i>J</i> = 8.2 Hz), 7.46 (1H, d, <i>J</i> = 2.2 Hz), 7.31 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.28–7.24 (1H, m), 7.09 (1H, td, <i>J</i> = 7.4, 1.1 Hz), 7.02 (2H, s), 2.89 (2H, q, <i>J</i> = 7.5 Hz), 1.35 (3H, t, <i>J</i> = 7.4 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.00, 162.99, 158.02, 151.11, 139.79, 136.75, 135.47, 130.96, 127.96, 127.39, 125.40, 124.27, 122.16, 119.85, 118.24, 117.01, 112.38, 106.37, 103.00, 21.93, 12.11. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 371.1620, found: 371.1625.</div></div></div><div id="sec6_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure D for Synthesis of Aryl Hydrazines <b>10c</b> and <b>11c</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>)</h3><div id="sec6_1_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 5-Bromo-1-(<i>p</i>-tolylsulfonyl)indole (<b>10a</b>)</h4><div class="NLM_p">5-Bromo-1<i>H</i>-indole (1.96 g, 10.0 mmol) was dissolved in THF (20 mL), and then NaH (60% in mineral oil, 520 mg, 13.0 mmol) was added to the mixture at 0 °C. The mixture was stirred at 25 °C for 15 min under nitrogen atmosphere. TsCl (tosyl chloride) (2.29 g, 12.0 mmol) was added to the mixture at 0 °C, and then the mixture was stirred at 25 °C for 18 h under nitrogen atmosphere. The mixture was diluted with H<sub>2</sub>O (20 mL) with ice-cooling. The mixture was extracted with AcOEt (20 mL × 2), and then the combined organic layers were washed with brine (20 mL). The organic layer was dried on Na<sub>2</sub>SO<sub>4</sub>, and then the desiccant was removed by filtration. The filtrate was concentrated under reduced pressure, and then the residue was diluted with dichloromethane (20 mL). The mixture was absorbed in ISOLUTE HM-N (Biotage, 10 g), and then the volatile was removed under reduced pressure. The powder was subjected to a silica gel column cartridge (100 g), and then the column was eluted with <i>n</i>-hexane-AcOEt by a linear gradient. The fractions containing the target were collected and concentrated under reduced pressure to give the titled compound as a colorless powder (3.03 g, 87%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.88–7.85 (5H, m), 7.48 (1H, dd, <i>J</i> = 8.8, 2.2 Hz), 7.39 (2H, d, <i>J</i> = 8.2 Hz), 6.81 (1H, d, <i>J</i> = 3.3 Hz), 2.32 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 145.67, 133.78, 132.83, 132.34, 130.23 (2C), 128.35, 127.12 (2C), 126.63, 123.96, 116.01, 114.89, 108.69, 20.93. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>12</sub>BrNO<sub>2</sub>S - H<sup>+</sup> [M - H]<sup>−</sup>: 347.9694, found: 347.9693.</div></div><div id="sec6_1_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>tert</i>-Butyl <i>N</i>-(<i>tert</i>-Butoxycarbonylamino)-<i>N</i>-[1-(<i>p</i>-tolylsulfonyl)indol-5-yl]carbamate (<b>10b</b>)</h4><div class="NLM_p">5-Bromo-1-(<i>p</i>-tolylsulfonyl)indole (<b>10a</b>, 350 mg, 1.00 mmol), <i>tert</i>-butyl <i>N</i>-(<i>tert</i>-butoxycarbonylamino)carbamate (279 mg, 1.20 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (489 mg, 1.50 mmol) were placed in a screw-capped vial, and then toluene (2.0 mL) was added thereto. Nitrogen gas was bubbled into the suspension for 30 s. Tris(dibenzylideneacetone)dipalladium(0) (Pd<sub>2</sub>(dba)<sub>3</sub>) (45.8 mg, 0.0500 mmol) and 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-tri<i>iso</i>-propyl-1,1′-biphenyl (<i>t</i>-Bu XPhos, 63.7 mg, 0.150 mmol) were added to the vial, and then nitrogen gas was bubbled into the suspension for 30 s. The mixture was stirred at 100 °C for 6 h under nitrogen atmosphere. The mixture was diluted with AcOEt (5 mL), and then the suspension was washed with H<sub>2</sub>O (5 mL) and brine (5 mL). The organic layer was concentrated under reduced pressure, and then the residue was diluted with DMSO (2 mL). The solution was subjected to a C<sub>18</sub> MPLC column, and then the column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected and concentrated under reduced pressure to give the titled compound as a light yellow amorphous (359 mg, 72%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.64 (1H, s), 7.87–7.85 (3H, m), 7.78 (1H, d, <i>J</i> = 3.5 Hz), 7.51 (1H, s), 7.37 (2H, d, <i>J</i> = 7.9 Hz), 7.28 (1H, d, <i>J</i> = 9.3 Hz), 6.85 (1H, d, <i>J</i> = 3.5 Hz), 2.31 (3H, s), 1.42 (18H, s). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>31</sub>N<sub>3</sub>O<sub>6</sub>S - H<sup>+</sup> [M - H]<sup>−</sup>: 500.1855, found: 500.1846.</div></div><div id="sec6_1_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> [1-(<i>p</i>-Tolylsulfonyl)indol-5-yl]hydrazine hydrochloride (<b>10c</b>)</h4><div class="NLM_p"><i>tert</i>-Butyl <i>N</i>-(<i>tert</i>-butoxycarbonylamino)-<i>N</i>-[1-(<i>p</i>-tolylsulfonyl)indol-5-yl]carbamate (<b>10b</b>, 300 mg, 0.598 mmol) was suspended in AcOEt (3.0 mL), and then 4 M HCl AcOEt (3.0 mL) was added to the suspension at 25 °C. The mixture was stirred at 25 °C for 4 h under nitrogen atmosphere. The precipitate was collected by filtration, and then the cake was washed with AcOEt (2 mL). The powder was dried under reduced pressure to give the titled compound as a colorless powder (156 mg, 77%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.08 (3H, br s), 8.19 (1H, s), 7.85–7.82 (3H, m), 7.75 (1H, d, <i>J</i> = 3.5 Hz), 7.37 (2H, d, <i>J</i> = 7.9 Hz), 7.14 (1H, d, <i>J</i> = 1.8 Hz), 7.01 (1H, dd, <i>J</i> = 9.0, 2.4 Hz), 6.79 (1H, d, <i>J</i> = 3.1 Hz), 2.31 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 145.30, 142.00, 133.92, 130.95, 130.06 (2C), 129.56, 127.78, 126.54 (2C), 113.64, 113.57, 109.36, 106.20, 20.91. MS (ESI): <i>m</i>/<i>z</i> 302 [M + H]<sup>+</sup>.</div></div><div id="sec6_1_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> [5-Amino-1-(1<i>H</i>-indol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>10</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.70 (1H, s), 11.40 (1H, s), 8.30 (1H, s), 7.71–7.69 (2H, m), 7.57 (1H, d, <i>J</i> = 8.8 Hz), 7.50–7.46 (3H, m), 7.25–7.23 (2H, m), 7.08 (1H, t, <i>J</i> = 7.1 Hz), 6.93 (2H, s), 6.56 (1H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.96, 151.06, 139.49, 136.72, 135.51, 135.07, 129.01, 127.52, 127.39, 127.03, 124.22, 122.14, 119.82, 118.11, 116.24, 112.36, 112.04, 106.28, 102.92, 101.73. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>15</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 342.1355, found: 342.136.</div></div><div id="sec6_1_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> [2-Methyl-1-(<i>p</i>-tolylsulfonyl)indol-5-yl]hydrazine hydrochloride (<b>11c</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_4" aria-label="general procedure D">general procedure D</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.06 (3H, s), 8.17 (1H, s), 7.92 (1H, d, <i>J</i> = 8.8 Hz), 7.71 (2H, d, <i>J</i> = 8.4 Hz), 7.36 (2H, d, <i>J</i> = 8.8 Hz), 7.02 (1H, d, <i>J</i> = 2.2 Hz), 6.94 (1H, dd, <i>J</i> = 9.0, 2.4 Hz), 6.53 (1H, d, <i>J</i> = 0.9 Hz), 2.57 (3H, d, <i>J</i> = 0.9 Hz), 2.32 (3H, s).; <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 145.15, 141.99, 138.05, 134.73, 131.37, 130.14 (2C), 129.87 (2C), 126.07, 114.38, 112.41, 109.78, 105.12, 20.90, 15.28. MS (ESI): <i>m</i>/<i>z</i> 316 [M + H]<sup>+</sup>.</div></div><div id="sec6_1_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> [5-Amino-1-(2-methyl-1<i>H</i>-indol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (<b>11</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.70 (1H, s), 11.22 (1H, s), 8.28 (1H, s), 7.70 (1H, d, <i>J</i> = 7.7 Hz), 7.55 (1H, s), 7.49–7.43 (3H, m), 7.25 (1H, t, <i>J</i> = 7.1 Hz), 7.15–7.06 (2H, m), 6.89 (2H, s), 6.25 (1H, s), 2.43 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.94, 150.97, 139.40, 137.47, 136.71, 135.52, 135.28, 128.82, 128.57, 127.39, 124.22, 122.13, 119.81, 116.95, 115.13, 112.36, 110.97, 106.27, 102.92, 99.73, 13.35. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 356.1511, found: 356.1518.</div></div><div id="sec6_1_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-Hydrazino-1,3-dihydrobenzimidazol-2-one hydrochloride (<b>12a</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_3" aria-label="general procedure C">general procedure C</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.66 (1H, s), 10.49 (1H, s), 10.06 (4H, s), 6.84 (1H, d, <i>J</i> = 8.4 Hz), 6.75 (1H, d, <i>J</i> = 1.3 Hz), 6.66 (1H, dd, <i>J</i> = 8.4, 1.8 Hz); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 155.93, 140.00, 130.64, 125.65, 109.10, 108.98, 98.05. MS (ESI): <i>m</i>/<i>z</i> 165 [M + H]<sup>+</sup>.</div></div><div id="sec6_1_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-[5-Amino-4-(1<i>H</i>-indole-2-carbonyl)pyrazol-1-yl]-1,3-dihydrobenzimidazol-2-one (<b>12</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.71 (1H, s), 10.97 (2H, br s), 8.30 (1H, s), 7.70 (1H, d, <i>J</i> = 7.7 Hz), 7.49 (1H, d, <i>J</i> = 8.2 Hz), 7.45 (1H, d, <i>J</i> = 1.1 Hz), 7.25 (1H, td, <i>J</i> = 7.7, 1.1 Hz), 7.12–7.09 (4H, m), 7.01 (2H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.96, 155.43, 151.02, 139.79, 136.74, 135.43, 130.29, 130.07, 129.35, 127.37, 124.27, 122.15, 119.84, 116.97, 112.38, 108.59, 106.38, 105.20, 102.95. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>14</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 359.1257, found: 359.1251.</div></div><div id="sec6_1_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-[5-(morpholinomethyl)-1<i>H</i>-indol-2-yl]methanone (<b>13</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.68 (1H, s), 8.31 (1H, s), 7.61–7.59 (3H, m), 7.44–7.42 (2H, m), 7.30 (1H, dd, <i>J</i> = 8.4, 2.2 Hz), 7.22 (1H, dd, <i>J</i> = 8.4, 1.3 Hz), 7.01 (2H, s), 3.58 (4H, t, <i>J</i> = 4.4 Hz), 3.53 (2H, s), 2.54 (3H, s), 2.37 (4H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.96, 163.72, 153.17, 151.07 (2C), 139.79, 136.12, 135.67, 132.46, 130.94, 129.04, 128.37, 127.26, 126.01, 122.27, 118.09, 112.12, 106.29, 102.99, 66.12 (2C), 62.91, 53.08 (2C), 14.64. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 456.2148, found: 456.2141.</div></div><div id="sec6_1_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-[6-(morpholinomethyl)-1<i>H</i>-indol-2-yl]methanone (<b>14</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.48 (1H, s), 11.66 (1H, s), 8.31 (1H, s), 7.63–7.61 (3H, m), 7.43 (1H, d, <i>J</i> = 1.6 Hz), 7.42 (1H, s), 7.30 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.06 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.00 (2H, s), 3.58 (4H, t, <i>J</i> = 4.4 Hz), 3.35 (2H, s), 2.54 (3H, s), 2.38 (4H, br s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.04, 153.25, 151.17, 143.60, 139.85, 136.98, 135.63, 134.35, 134.04, 131.14, 126.70, 121.91, 121.65, 118.55, 117.93, 112.51, 111.18, 106.47, 103.08, 66.24 (2C), 63.16, 53.27 (2C), 14.72. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>25</sub>N7O2 + H<sup>+</sup> [M + H]<sup>+</sup>: 456.2148, found: 456.2138.</div></div><div id="sec6_1_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-[6-[(4,4-difluoro-1-piperidyl)methyl]-1<i>H</i>-indol-2-yl]methanone (<b>15</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.48 (1H, s), 11.67 (1H, s), 8.31 (1H, s), 7.63–7.60 (3H, m), 7.43 (1H, d, <i>J</i> = 2.2 Hz), 7.42 (1H, s), 7.30 (1H, d, <i>J</i> = 8.2 Hz), 7.06 (1H, dd, <i>J</i> = 8.2, 1.1 Hz), 6.99 (2H, s), 3.63 (2H, s), 2.54 (3H, s), 2.51–2.49 (4H, m), 2.01–1.91 (4H, m); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.04, 153.25, 151.17, 143.59, 139.86, 136.98, 135.68, 134.65, 134.41, 130.97, 126.74, 122.88 (t, <i>J</i> = 240.7 Hz), 121.96, 121.53, 118.54, 117.86, 112.40, 111.20, 106.47, 103.09, 61.61, 49.33 (2C, t, <i>J</i> = 5.0 Hz), 33.50 (2C, t, <i>J</i> = 22.4 Hz), 14.72. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>25</sub>F<sub>2</sub>N<sub>7</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 490.2167, found: 490.2158.</div></div><div id="sec6_1_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-[6-Iodo-1-(<i>p</i>-tolylsulfonyl)indol-2-yl]-3-oxo-propanenitrile (<b>16a</b>)</h4><div class="NLM_p">Ethyl 6-iodo-1-(<i>p</i>-tolylsulfonyl)indole-2-carboxylate (<b>14a</b>, 469 mg, 1.00 mmol) was dissolved in THF (4.7 mL), and then MeCN (0.157 mL, 3.00 mmol) was added to the solution. LHMDS (1.3 M in THF, 3.86 mL, 5.00 mmol) was added to the mixture at −78 °C over 10 min, and then the mixture was stirred at −78 °C for 1 h under nitrogen atmosphere. 10% AcOH (13 mL) was added at −78 °C, and then the mixture was warmed up to 25 °C. The volatile was removed under reduced pressure to dryness, and then MeOH (5 mL) was added to the suspension. The suspension was stirred at 25 °C for 1 h, and then H<sub>2</sub>O (5 mL) was added to the suspension at 25 °C. The precipitate was collected by filtration, and then the cake was washed with MeOH/H<sub>2</sub>O (1/2, 2 mL). The powder was dried under reduced pressure. The powder was dissolved in DMSO (5 mL), and then the solution was subjected to a C<sub>18</sub> MPLC column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target were collected and concentrated under reduced pressure to give the titled compound as a light brown powder (397 mg, 86 mg).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.52 (1H, s), 7.67 (2H, d, <i>J</i> = 8.8 Hz), 7.62 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.29 (1H, d, <i>J</i> = 8.2 Hz), 7.24 (2H, d, <i>J</i> = 8.2 Hz), 7.13 (1H, s), 4.13 (2H, s), 2.36 (3H, s); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 181.94, 146.04, 139.49, 136.94, 134.34, 133.10, 129.83 (2C), 127.81, 127.43 (2C), 124.95, 124.41, 119.30, 113.34, 93.78, 32.41, 21.69. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>13</sub>IN<sub>2</sub>O<sub>3</sub>S – H<sup>+</sup> [M – H]<sup>−</sup>: 462.9613, found: 462.9608.</div></div><div id="sec6_1_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>E</i>)-3-(Dimethylamino)-2-[6-iodo-1-(<i>p</i>-tolylsulfonyl)indole-2-carbonyl]prop-2-enenitrile (<b>16b</b>)</h4><div class="NLM_p">3-[6-Iodo-1-(<i>p</i>-tolylsulfonyl)indol-2-yl]-3-oxo-propanenitrile (<b>16a</b>, 338 mg, 0.728 mmol) was dissolved in THF (3.3 mL), and then DMF-DMA (0.107 mL, 0.801 mmol) was added to the solution at 25 °C. The mixture was stirred at 25 °C for 1 h under nitrogen atmosphere, and then <i>n</i>-hexane (2 mL) was added to the solution. The precipitate was collected by filtration, and then the cake was washed with <i>n</i>-hexane (1 mL). The powder was dried under reduced pressure to give the titled compound as a yellow amorphous (359 mg, 95%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.25 (1H, s), 7.97–7.95 (3H, m), 7.63 (1H, dd, <i>J</i> = 8.5, 1.4 Hz), 7.48 (1H, d, <i>J</i> = 8.2 Hz), 7.45 (2H, d, <i>J</i> = 8.2 Hz), 7.03 (1H, s), 3.40 (3H, s), 3.31 (3H, s), 2.36 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 181.24, 158.63, 145.74, 137.37, 136.67, 134.28, 132.67, 130.05 (2C), 128.01, 127.22 (2C), 127.08, 124.29, 122.35, 118.89, 112.14, 91.00, 47.67, 38.92, 21.08. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>18</sub>IN<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup> [M + H]<sup>+</sup>: 520.0192, found: 520.0197.</div></div><div id="sec6_1_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-[6-iodo-1-(<i>p</i>-tolylsulfonyl)indol-2-yl]methanone (<b>16c</b>)</h4><div class="NLM_p">(<i>E</i>)-3-(Dimethylamino)-2-[6-iodo-1-(<i>p</i>-tolylsulfonyl)indole-2-carbonyl]prop-2-enenitrile (<b>16b</b>, 331 mg, 0.637 mmol) was dissolved in NMP (3.3 mL), and then 4-methylmorpholine (0.210 mL, 1.91 mmol) was added to the solution. Nitrogen gas was bubbled into the solution, and then (2-methyl-3<i>H</i>-benzimidazol-5-yl)hydrazine dihydrochloride (300 mg, 1.28 mmol) was added to the mixture. The mixture was stirred at 100 °C for 30 min under nitrogen atmosphere. The mixture was dissolved in DMSO (3 mL), and then the solution was subjected to a C<sub>18</sub> MPLC column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target was collected and concentrated under reduced pressure to give the titled compound as a light brown amorphous (331 mg, 82%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.61 (1H, s), 8.31 (1H, s), 8.01 (2H, d, <i>J</i> = 8.2 Hz), 7.77 (1H, s), 7.67 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.63–7.62 (2H, m), 7.52 (1H, d, <i>J</i> = 8.2 Hz), 7.48 (2H, d, <i>J</i> = 8.2 Hz), 7.30 (1H, dd, <i>J</i> = 8.2, 2.2 Hz), 7.25 (1H, s), 7.06 (2H, s), 2.54 (3H, s), 2.38 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.10, 163.05, 158.83, 153.31, 150.65, 145.64, 141.18, 138.22, 137.44, 134.52, 132.83, 130.82, 130.06 (2C), 129.18, 127.99, 127.26 (2C), 126.40, 124.58, 122.77, 118.18, 113.82, 105.07, 91.50, 21.12, 14.69. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>21</sub>IN<sub>6</sub>O<sub>3</sub>S + H<sup>+</sup> [M + H]<sup>+</sup>: 637.0519, found: 637.0517.</div></div><div id="sec6_1_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(6-methylsulfonyl-1<i>H</i>-indol-2-yl)methanone (<b>16</b>)</h4><div class="NLM_p">[5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-[6-iodo-1-(<i>p</i>-tolylsulfonyl)indol-2-yl]methanone (<b>16c</b>, 63.6 mg, 0.100 mmol), sodium methansulfinate (20.4 mg, 0.22 mmol), (1<i>S</i>,2<i>S</i>)-<i>N</i>1,<i>N</i>2-dimethylcyclohexane-1,2-diamine (2.84 mg, 0.0200 mmol), and CuI (1.91 mg, 0.0010 mmol) were placed in a round-bottomed flask, and then DMSO (0.4 mL) was added to the mixture. The flask was evacuated and then backfilled with nitrogen. The mixture was stirred at 120 °C for 18 h under nitrogen atmosphere. Five M NaOH (0.400 mL) was added to the mixture, and then the mixture was stirred at 80 °C for 1 h under nitrogen atmosphere. The mixture was dissolved in DMSO (1 mL), and then the solution was subjected to a C<sub>18</sub> MPLC column. The column was eluted with 0.1% formic acid-H<sub>2</sub>O-MeCN by a linear gradient. The fractions containing the target was concentrated under reduced pressure to give the titled compound as a light yellow powder (18 mg, 41%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.33 (1H, s), 8.36 (1H, s), 8.14 (1H, s), 8.06 (1H, s), 7.95 (1H, d, <i>J</i> = 8.2 Hz), 7.64–7.60 (4H, m), 7.32 (1H, dd, <i>J</i> = 8.5, 1.9 Hz), 7.12 (2H, s), 3.22 (4H, s), 2.56 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.49, 163.06, 162.00, 153.31, 151.47, 139.98, 138.93, 136.00, 135.15, 131.09, 130.70, 128.04, 125.49, 123.25, 118.52, 117.66, 112.44, 106.10, 103.22, 44.21, 14.60. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O<sub>3</sub>S + H<sup>+</sup> [M + H]<sup>+</sup>: 435.1239, found: 435.1242.</div></div><div id="sec6_1_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(6-bromo-1<i>H</i>-indol-2-yl)methanone (<b>17</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.84 (1H, s), 8.31 (1H, s), 8.19 (1H, s), 7.68–7.66 (2H, m), 7.61 (1H, d, <i>J</i> = 2.2 Hz), 7.49 (1H, d, <i>J</i> = 1.8 Hz), 7.29 (1H, dd, <i>J</i> = 8.6, 2.0 Hz), 7.22 (1H, dd, <i>J</i> = 8.4, 1.8 Hz), 7.03 (2H, s), 2.54 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.57, 163.56, 153.18, 151.17, 145.69, 139.72, 137.41, 136.18, 130.86, 127.93, 126.40, 125.39, 124.04, 122.90, 118.12, 117.01, 114.77, 106.37, 102.97, 20.67. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>15</sub>BrN<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 435.0569, found: 435.0564.</div></div><div id="sec6_1_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(6-methyl-1<i>H</i>-indol-2-yl)methanone (<b>18</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.58 (1H, s), 11.57 (1H, s), 8.30 (1H, s), 8.14 (1H, s), 7.61–7.58 (2H, m), 7.41 (1H, d, <i>J</i> = 1.6 Hz), 7.30 (1H, dd, <i>J</i> = 8.5, 1.9 Hz), 7.27 (1H, s), 6.99 (2H, s), 6.92 (1H, dd, <i>J</i> = 8.2, 1.1 Hz), 2.54 (3H, s), 2.42 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 178.06, 163.07, 153.24, 151.13, 139.82, 137.55, 137.36, 135.12, 133.90, 131.10, 128.01, 125.49, 125.46, 122.07, 121.97, 118.20, 111.95, 106.60, 103.05, 21.68, 14.71. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 371.1620, found: 371.1624.</div></div><div id="sec6_1_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(6-phenyl-1<i>H</i>-indol-2-yl)methanone (<b>19</b>)</h4><div class="NLM_p">Prepared by following the <a class="ref internalNav" href="#sec6_1_2" aria-label="general procedure B">general procedure B</a>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.83 (1H, s), 8.39 (1H, s), 8.35 (1H, s), 7.79 (1H, d, <i>J</i> = 8.2 Hz), 7.71–7.69 (3H, m), 7.63–7.62 (2H, m), 7.51–7.48 (3H, m), 7.41 (1H, dd, <i>J</i> = 8.2, 1.6 Hz), 7.39–7.35 (1H, m), 7.30 (1H, dd, <i>J</i> = 8.5, 1.9 Hz), 7.04 (2H, s), 2.54 (3H, s); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 177.85, 153.31, 151.23, 141.17, 139.85, 137.45, 136.73, 136.29, 131.00, 129.18, 128.97 (2C), 128.85, 128.04, 127.05, 126.99, 126.83 (2C), 125.49, 122.76, 119.65, 118.16, 110.21, 106.41, 103.11, 14.72. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C26H<sub>20</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 433.1777, found: 433.1784.</div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Crystallization and Structural Determination of Binary Complex of FGFR1 and Compound <b>8</b></h3><div class="NLM_p last">Protein crystallization and determination of structure of binary complex of FGFR1 and <b>8</b> were performed by Roche. The details have been described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3D Modeling of Compounds</h3><div class="NLM_p last">The 3D model structures were generated by using Discovery Studio. Modeled bound conformations to FGFR1 of the <b>1</b> and <b>4</b> were modeled manually based on the experimentally determined bound conformation of a derivative of <b>1</b> (RO3201195) to p38α (PDB code:2BAQ). Then these modeled bound conformations were optimized in the FGFR1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>, a complex of FGFR1 and <b>20</b>) with all non-hydrogen atoms of FGFR1 fixed (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The 3D model structures of <b>4</b>, FGFR1, KDR, and SRC in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,B were generated by being superimposed at hinge region of FGFR1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>), KDR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WZD">2WZD</a>, a complex of KDR and ADP), and SRC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D">3G5D</a>, a complex of SRC and dasatinib). The 3D model structure in <a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a>C,D and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B was generated by being overlapped the model structure of <b>4</b> and FGFR1 with the crystal structure of binary complex of <b>8</b> and FGFR1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>). The overlapped structure of <b>8</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>), <b>21</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN">4WUN</a>), <b>22</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0">3TT0</a>), and FGFR1 in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C was generated by being overlapped at the hinge region of FGFR1.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Calculation of p<i>K</i><sub>a</sub> Values</h3><div class="NLM_p last">The p<i>K</i><sub>a</sub> values were calculated in a prediction software (Moka 2.0) developed by Molecular Discovery. <a href="http://www.moldiscovery.com/" class="extLink">http://www.moldiscovery.com/</a>.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Caco2 Assay</h3><div class="NLM_p last">Caco-2 cells were grown on culture flasks in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%FBS, 1% nonessential amino acids, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air. Cells were harvested with trypsin-EDTA and seeded onto polyester filters (1.0 μm pores, 0.14 cm<sup>2</sup> growth area) inside Transwell cell culture chambers (Costar, Cambridge, MA) at a density of 2.8 × 10<sup>4</sup> cells/filter. The culture medium was changed every other day. The cells were cultured for 2 weeks, and the Caco-2 monolayers were utilized for the following assay. Apical to basolateral permeability assays were carried out with apical and basolateral Hanks’ Balanced Salt Solution (HBSS) adjusted at 6.0 and 7.4, respectively (HBSS with 4% bovine serum albumin (BSA) in basolateral compartment). The donor concentration of test compound was set at 10 μmol/L, and basolateral compartment was sampled at 120 min. The compound concentration in basolateral compartment was measured by LC-MS/MS. The apparent permeability coefficient (Papp) value was calculated from the following equation: Papp (cm/s) = <i>Q</i>/<i>t</i>/<i>A</i>/<i>C</i><sub>0</sub> where <i>Q</i>, <i>t</i>, <i>A</i>, and <i>C</i><sub>0</sub> represent permeation amount of the compound (nmol), incubation time (s), surface area of cell monolayer (cm<sup>2</sup>) and initial concentration of test compound (μmol/L).</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Intrinsic Clearance (CL<sub>int</sub>) Determination in Microsomes</h3><div class="NLM_p last">Each compound (1 μM) was incubated with human (or mouse) liver microsome (0.5 mg protein/mL) in 50 mM phosphate buffer (pH 7.4) containing 1 mM NADPH (the reduced form of nicotinamide adenine dinucleotide phosphate) at 37 °C for 30 min. After the enzyme reaction was terminated with the addition of a 3-fold volume of acetonitrile, the reaction mixture was centrifuged at 1500 rpm for 10 min. The resultant supernatant was used as a test sample to measure the stability in human (or mouse) liver microsome by quantitating the compound in the sample using LC/MS.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Solubility Assay</h3><div class="NLM_p last">An aliquot of 50 μL of 4 mM or 1 mM sample in DMSO was freeze-dried to remove DMSO. To the resulting residue was added 50 μL of FaSSIF (pH = 6.5), which was then irradiated ultrasonically for 10 min, shaken for 2 h, centrifuged for 10 min (3000 rpm), and filtered by Whatman Unifilter. Concentration of the filtrate was analyzed by HPLC-UV based on the calibration curve of each sample. Composition of FaSSIF: Sodium taurocholate (1.61 g), lecithin (0.59 g), KH<sub>2</sub>PO<sub>4</sub> (3.9 g), KCl (7.7 g), and NaOH (pH 6.5) per 1 L.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Protein Kinase Enzyme Assay</h3><div class="NLM_p last">The measurement of inhibitory activities against kinases and cell proliferation was described previouly.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Cell Proliferation Assay</h3><div class="NLM_p last">Cell lines were obtained from American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Health Science Research Resources Bank (HSRRB), Asterand Inc., and Health Protection Agency Culture Collections (HPACC). All cell lines were authenticated by the cell banks with cytogenic analysis, DNA profiling, or growth properties and were propagated for <6 months after resuscitation. Also, all cell lines were cultured according to supplier instructions. The cell lines were added to the wells of 96-well plates containing 0.076–10,000 nM tested compounds and incubated at 37 °C. After 4 days’ incubation, Cell Counting Kit-8 solution (Dojindo Laboratories) was added, and after incubation for several more hours, absorbance at 450 nm was measured with the iMark Microplate-Reader (Bio-Rad Laboratories). The antiproliferative activity was calculated using the formula (1 – <i>T</i>/<i>C</i>) × 100 (%), where <i>T</i> and <i>C</i> represent absorbance at 450 nm of the cells treated with drugs (<i>T</i>) and that of untreated control cells (<i>C</i>). The IC<sub>50</sub> values were calculated using Microsoft Excel 2007.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> PK Study in Monkeys</h3><div class="NLM_p last">All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Chugai Pharmaceutical Co. Ltd. The compounds were dissolved in 10% DMSO/10% Cremophor-EL/15% PEG400/15% HPCD as a vehicle and were administered intravenously (i.v.) or orally (p.o.) to cynomolgus monkeys at 0.5 or 1 mg/kg. Two animals were used for i.v. or p.o. group, and blood was collected at 5, 15 min, 1, 2, 4, 7, 24, and 48 h or 30 min, 1, 2, 4, 7, 24, and 48 h for i.v. or p.o. administration, respectively. Heparin was used as an anticoagulant, and plasma was obtained by centrifugation. Plasma concentration of the test compounds was measured by LC-MS/MS. Pharmacokinetic parameters were calculated using WATSON software. Area under the plasma concentration versus time curve (AUC) was calculated by linear-log trapezoidal rule and bioavailability (BA, %) was calculated by (AUC<sub>p.o.</sub>/AUC<sub>i.v.</sub>) × (Dose<sub>i.v.</sub>/Dose<sub>p.o.</sub>).</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> hERG Assay</h3><div class="NLM_p last">The hERG currents were measured by a whole-cell patch clamp technique using an automated patch-clamp system (PatchXpress 7000A) at ambient temperature. Chinese hamster ovary (CHO) cells stably expressing hERG were used in this study.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The extracellular solution contained (mM): NaCl 150; KCl 4; CaCl<sub>2</sub> 1.2; MgCl<sub>2</sub> 1; HEPES 10; glucose 10; pH 7.4 with NaOH. The internal solution contained (mM): KCl 140; EGTA 5; HEPES 10; MgCl<sub>2</sub> 1; MgATP 5; pH 7.2 with KOH. The cells were held at a voltage of −80 mV and stimulated by a voltage pattern (baseline voltage step to −40 mV for 0.1 s, prepulse voltage step to +20 mV for 1 s, test pulse voltage step to −40 mV for 0.5 s) every 10 s. The compounds were cumulatively applied to the cells at concentrations of 1 and 10 μM. The inhibition rates of the hERG current were corrected by the vehicle control (0.1% DMSO) to obtain a % inhibition of the hERG current (% hERG inhibition). The % hERG inhibition of each compound was averaged by the results of 3–4 cells. The hERG IC<sub>50</sub> was calculated by a linear regression analysis based on the % hERG inhibition at 1 and 10 μM.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Mouse Xenograft Study</h3><div class="NLM_p last">The in vivo studies were approved by the Chugai Institutional Animal Care and Use Committee. Female BALB-<i>nu</i>/<i>nu</i> mice (CAnN.Cg-Foxn1 ⟨nu⟩/CrlCrlj <i>nu</i>/<i>nu</i>) were obtained from Charles River Laboratories Japan and kept under specified pathogen-free conditions. Cells (4 × 10<sup>6</sup> – 1.1 × 10<sup>7</sup>) were suspended in 100–200 μL serum-free culture medium and injected subcutaneously into the right flank of the mice. Tumor size was measured using a gauge twice per week, and tumor volume (TV) was calculated using the following formula: TV = <i>ab</i><sup>2</sup>/2, where <i>a</i> is the length of the tumor, and <i>b</i> is the width. Once the tumors reached a volume of approximately 200–300 mm<sup>3</sup>, animals were randomized into groups (<i>n</i> = 3, 4, or 5 in each group), and treatment was initiated. Compound <b>8</b> was orally administered once a day.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01156">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77251" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77251" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01156" class="ext-link">10.1021/acs.jmedchem.6b01156</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details and data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_001.pdf">jm6b01156_si_001.pdf (1.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_002.csv">jm6b01156_si_002.csv (5.17 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors released the atomic coordinates and experimental data for FGFR1 complex with compound <b>8</b> in the PDB under accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b01156" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hirosato Ebiike</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8de8efe4e4e6e8e5fffecdeee5f8eaece4a0fde5ecffe0a3eee2a3e7fd"><span class="__cf_email__" data-cfemail="680d0a0101030d001a1b280b001d0f0901451800091a05460b07460218">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naoki Taka</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masayuki Matsushita</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masayuki Ohmori</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyoko Takami</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ikumi Hyohdoh</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masami Kohchi</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tadakatsu Hayase</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroki Nishii</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenji Morikami</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshito Nakanishi</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nukinori Akiyama</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hidetoshi Shindoh</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nobuya Ishii</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takehito Isobe</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroharu Matsuoka</span> - <span class="hlFld-Affiliation affiliation">Research
Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d89e4468-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Hiroshi Koyano for helpful discussion; Masako Arai and Yoshiko Itezono for measuring the high resolution mass and NMR experiments; Fumie Sawamura for animal studies; Yasuko Satoh, Yukako Tachibana-Kondo, Yasue Nagata, and Tsutomu Takahashi for pharmacological assays; Santina Russo and Joachim Diez at Expose GmbH for protein crystallography; Dr. Takaaki Fukami for submission of 3D structure data to the PDB (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>); Lisha Wang and Weili Zhao for design and synthesis of inhibitors.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i74" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i74"> Abbreviations Used</h2><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">BCR-ABL</td><td class="NLM_def"><p class="first last">breakpoint cluster region abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">B-Raf</td><td class="NLM_def"><p class="first last">B-Raf proto-oncogene, serine/threonine kinase</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">erb-b2 receptor tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">SRC proto-oncogene, non-receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">AcOEt</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">BocNHNHBoc</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl hydrazodiformate</p></td></tr><tr><td class="NLM_term">Bs</td><td class="NLM_def"><p class="first last">benzenesulfonyl</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF-DMA</td><td class="NLM_def"><p class="first last">dimethylformamide dimethyl acetal</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">LHMDS</td><td class="NLM_def"><p class="first last">MeCN, acetonitrile</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MPLC</td><td class="NLM_def"><p class="first last">medium-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">PDA</td><td class="NLM_def"><p class="first last">photodiode array</p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">acid dissociation constant</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu XPhos</td><td class="NLM_def"><p class="first last">2-di-<i>tert</i>-butylphosphino-2′,4′,6′-tri-<i>iso</i>-propyl-1,1′-biphenyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TsCl</td><td class="NLM_def"><p class="first last">tosyl chloride</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultra-high-performance liquid chromatography</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Pagliarini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.15252/embr.201439949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.15252%2Fembr.201439949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25680965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=280-296&author=R.+Pagliariniauthor=W.+Shaoauthor=W.+R.+Sellers&title=Oncogene+addiction%3A+pathways+of+therapeutic+response%2C+resistance%2C+and+road+maps+toward+a+cure&doi=10.15252%2Fembr.201439949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span></div><div class="casAuthors">Pagliarini, Raymond; Shao, Wenlin; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-296</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival.  While most cancers harbor multiple oncogenic mutations, a wealth of preclin. and clin. data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'.  Herein, we describe the clin. evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene-targeted therapies.  Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEtJj2YdGf6LVg90H21EOLACvtfcHk0lhepBmpF5ssHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D&md5=30f0b2a45a633e12155d5c7e577753e2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.15252%2Fembr.201439949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201439949%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DOncogene%2520addiction%253A%2520pathways%2520of%2520therapeutic%2520response%252C%2520resistance%252C%2520and%2520road%2520maps%2520toward%2520a%2520cure%26jtitle%3DEMBO%2520Rep.%26date%3D2015%26volume%3D16%26spage%3D280%26epage%3D296%26doi%3D10.15252%2Fembr.201439949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Saijo, N.</span><span> </span><span class="NLM_article-title">Present status and problems on molecular targeted therapy of cancer</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.4143/crt.2012.44.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.4143%2Fcrt.2012.44.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A280%3ADC%252BC38rkslChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=1-10&author=N.+Saijo&title=Present+status+and+problems+on+molecular+targeted+therapy+of+cancer&doi=10.4143%2Fcrt.2012.44.1.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Present status and problems on molecular targeted therapy of cancer</span></div><div class="casAuthors">Saijo Nagahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Numerous clinical trials of molecular targeted drugs for cancer have been conducted, with remarkable results for certain drugs and accumulation of "negative data" causing a hitch in the development plan for some other compounds.  Five recent issues and problems of molecular targeted therapies were discussed critically.  Drug discovery and effects against driver mutations (activating mutations) and problems: possibility for circumventing inherent and acquired resistance with the aim of achieving radical cure.  Synthetic lethality: reasonable patient selection in individualized treatment strategy.  Response rate and progression-free survival improvement with or without overall survival benefit and enhancement of toxicity in bevacizumab therapy: best endpoints for the evaluation of effect of antiangiogenic therapy.  Negative data on small-molecule targeted therapy, primarily vascular endothelial growth factor tyrosine kinase inhibitors: loose GO or NO-GO decision criteria for further development of new compounds in early clinical trials.  Effect of immunotherapy: difficulty to verify by proof of principle study.  We are faced to many questions for the development of efficient personalized therapy.  Accumulation of scientific global preclinical and clinical evidences is essential to use these new therapeutic modalities for the improvement of oncologic health care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCEHsxuDVeOqqcneEtCi92fW6udTcc2eaQj1U6fJ2Zs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkslChsg%253D%253D&md5=c5375ca0a4c6617c4759862d296d90e4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2012.44.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2012.44.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DN.%26atitle%3DPresent%2520status%2520and%2520problems%2520on%2520molecular%2520targeted%2520therapy%2520of%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D44%26spage%3D1%26epage%3D10%26doi%3D10.4143%2Fcrt.2012.44.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Walker, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, A. H.</span><span> </span><span class="NLM_article-title">Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2224</span><span class="NLM_x">–</span> <span class="NLM_lpage">2236</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i9.2224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.3748%2Fwjg.v20.i9.2224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlOnsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2224-2236&author=E.+J.+Walkerauthor=A.+H.+Ko&title=Beyond+first-line+chemotherapy+for+advanced+pancreatic+cancer%3A+an+expanding+array+of+therapeutic+options%3F&doi=10.3748%2Fwjg.v20.i9.2224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?</span></div><div class="casAuthors">Walker, Evan J.; Ko, Andrew H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2224-2236</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  While an increasing no. of therapeutic options are now available for the first-line treatment of locally advanced or metastatic pancreatic cancer, the optimal choice for treatment in the second-line setting and beyond is less well defined.  A variety of cytotoxic agents, either alone or in combination, have been evaluated, although primarily in the context of small single-arm or retrospective studies.  Most regimens have been assocd. with median progression-free survival rates in the range of 2-4 mo and overall survival rates between 4-8 mo, highlighting the very poor prognosis of patients who are candidates for such treatment.  Targeted therapies studied in this chemotherapy-refractory setting, meanwhile, have produced even worse efficacy results.  In the current article, we review the clin. evidence for treatment of refractory disease, primarily in patients who have progressed on front-line gemcitabine-based chemotherapy.  In the process, we highlight the limitations of the available data to date as well as some of the challenges in designing appropriate clin. trials in this salvage setting, including how to select an appropriate control arm given the absence of a wellestablished ref. std., and the importance of incorporating predictive biomarkers and quality of life measures whenever possible into study design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRwFSWHsYM_7Vg90H21EOLACvtfcHk0lh6mO4wHQ0mSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlOnsLjK&md5=2018712a8e7bed3ca5be83f8fd66b2e3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i9.2224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i9.2224%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BJ.%26aulast%3DKo%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520first-line%2520chemotherapy%2520for%2520advanced%2520pancreatic%2520cancer%253A%2520an%2520expanding%2520array%2520of%2520therapeutic%2520options%253F%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D2224%26epage%3D2236%26doi%3D10.3748%2Fwjg.v20.i9.2224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Dieci, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnedos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0lh6mO4wHQ0mSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lh6mO4wHQ0mSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalenc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Garcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deudon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yovine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3693</span><span class="NLM_x">–</span> <span class="NLM_lpage">3702</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F1078-0432.CCR-13-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=23658459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3693-3702&author=F.+Andreauthor=T.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+Turnerauthor=H.+Rugoauthor=J.+W.+Smithauthor=S.+Deudonauthor=M.+Shiauthor=Y.+Zhangauthor=A.+Kayauthor=G.+D.+Portaauthor=A.+Yovineauthor=J.+Baselga&title=Targeting+FGFR+with+dovitinib+%28TKI258%29%3A+preclinical+and+clinical+data+in+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span></div><div class="casAuthors">Andre, Fabrice; Bachelot, Thomas; Campone, Mario; Dalenc, Florence; Perez-Garcia, Jose M.; Hurvitz, Sara A.; Turner, Nicholas; Rugo, Hope; Smith, John W.; Deudon, Stephanie; Shi, Michael; Zhang, Yong; Kay, Andrea; Graus Porta, Diana; Yovine, Alejandro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3693-3702</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are obsd. in approx. 10% of breast cancers and are related to poor outcomes.  We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers.  Exptl. Design: Preclin. activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2).  Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-neg. metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.  FGFR1 amplification was assessed by silver in situ hybridization.  Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quant. PCR (qPCR).  Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines.  Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.  Eighty-one patients were enrolled in the trial.  Unconfirmed response or stable disease for more than 6 mo was obsd. in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-pos. and FGFR1-nonamplified/HR-pos. breast cancer.  When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-pos. patients, the mean redn. in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.  Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification.  Clin Cancer Res; 19(13); 3693-702. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqsUkPK9d9YrVg90H21EOLACvtfcHk0lj3Klt5J8CtgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK&md5=8c6e6a67540e15a67ea71c93eeda92a9</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%2BW.%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DG.%2BD.%26aulast%3DYovine%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeting%2520FGFR%2520with%2520dovitinib%2520%2528TKI258%2529%253A%2520preclinical%2520and%2520clinical%2520data%2520in%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3693%26epage%3D3702%26doi%3D10.1158%2F1078-0432.CCR-13-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F0008-5472.CAN-04-4409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+P.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+J%C3%BCrgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+a+highly+potent%2C+orally+bioavailable%2C+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F0008-5472.CAN-04-4409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4409%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400%26doi%3D10.1158%2F0008-5472.CAN-04-4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Launay-Vacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deray, G.</span><span> </span><span class="NLM_article-title">Hypertension and proteinuria: a class-effect of antiangiogenic therapies</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e3283161012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1097%2FCAD.0b013e3283161012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=81-82&author=V.+Launay-Vacherauthor=G.+Deray&title=Hypertension+and+proteinuria%3A+a+class-effect+of+antiangiogenic+therapies&doi=10.1097%2FCAD.0b013e3283161012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e3283161012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e3283161012%26sid%3Dliteratum%253Aachs%26aulast%3DLaunay-Vacher%26aufirst%3DV.%26aulast%3DDeray%26aufirst%3DG.%26atitle%3DHypertension%2520and%2520proteinuria%253A%2520a%2520class-effect%2520of%2520antiangiogenic%2520therapies%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D81%26epage%3D82%26doi%3D10.1097%2FCAD.0b013e3283161012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gavine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0liezVDv2mwxdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudge, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span> </span><span class="NLM_article-title">Protein–ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5012</span><span class="refDoi"> DOI: 10.1021/jm3004043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5003-5012&author=R.+A.+Normanauthor=A.-K.+Schottauthor=D.+M.+Andrewsauthor=J.+Breedauthor=K.+M.+Footeauthor=A.+P.+Garnerauthor=D.+Oggauthor=J.+P.+Ormeauthor=J.+H.+Pinkauthor=K.+Robertsauthor=D.+A.+Rudgeauthor=A.+P.+Thomasauthor=A.+G.+Leach&title=Protein%E2%80%93ligand+crystal+structures+can+guide+the+design+of+selective+inhibitors+of+the+FGFR+tyrosine+kinase&doi=10.1021%2Fjm3004043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Fjm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004043%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DSchott%26aufirst%3DA.-K.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26atitle%3DProtein%25E2%2580%2593ligand%2520crystal%2520structures%2520can%2520guide%2520the%2520design%2520of%2520selective%2520inhibitors%2520of%2520the%2520FGFR%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5003%26epage%3D5012%26doi%3D10.1021%2Fjm3004043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Yosaatmadja, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, C. J.</span><span> </span><span class="NLM_article-title">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1107/S1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25760602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+%C3%85+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2FS1399004714027539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Patterson, Adam Vorn; Smaill, Jeff Bruce; Squire, Christopher John</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">1399-0047</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family are expressed widely in normal tissues and play a role in tissue repair, inflammation, angiogenesis and development.  However, aberrant signalling through this family can lead to cellular proliferation, evasion of apoptosis and induction of angiogenesis, which is implicated in the development of many cancers and also in drug resistance.  The high frequency of FGFR amplification or mutation in multiple cancer types is such that this family has been targeted for the discovery of novel, selective drug compds., with one of the most recently discovered being AZD4547, a subnanomolar (IC50) FGFR1 inhibitor developed by AstraZeneca and currently in clin. trials.  The 1.65 Å resoln. crystal structure of AZD4547 bound to the kinase domain of FGFR1 has been detd. and reveals extensive drug-protein interactions, an integral network of water mols. and the tight closure of the FGFR1 P-loop to form a long, narrow crevice in which the AZD4547 mol. binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjQbdbZHvbhbVg90H21EOLACvtfcHk0liezVDv2mwxdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D&md5=e7afc5e7d14f6879fee79b998a46e0b4</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520%25C3%2585%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2FS1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, D. G.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+G.+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0liasRh5kaJzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Miyake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugano, K.</span><span> </span><span class="NLM_article-title">1-<i>tert</i>-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-<i>d</i>]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G<sub>1</sub>/G<sub>0</sub> arrest</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1124/jpet.109.162768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1124%2Fjpet.109.162768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=19955487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFCjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=795-802&author=M.+Miyakeauthor=M.+Ishiiauthor=N.+Koyamaauthor=K.+Kawashimaauthor=T.+Kodamaauthor=S.+Anaiauthor=K.+Fujimotoauthor=Y.+Hiraoauthor=K.+Sugano&title=1-tert-Butyl-3-%5B6-%283%2C5-dimethoxy-phenyl%29-2-%284-diethylamino-butylamino%29-pyrido%5B2%2C3-d%5Dpyrimidin-7-yl%5D-urea+%28PD173074%29%2C+a+selective+tyrosine+kinase+inhibitor+of+fibroblast+growth+factor+receptor-3+%28FGFR3%29%2C+inhibits+cell+proliferation+of+bladder+cancer+carrying+the+FGFR3+gene+mutation+along+with+up-regulation+of+p27%2FKip1+and+G1%2FG0+arrest&doi=10.1124%2Fjpet.109.162768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest</span></div><div class="casAuthors">Miyake, Makito; Ishii, Masazumi; Koyama, Naoki; Kawashima, Kiyotaka; Kodama, Tetsuro; Anai, Satoshi; Fujimoto, Kiyohide; Hirao, Yoshihiko; Sugano, Kokichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-802</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activating mutation of the fibroblast growth factor receptor-3 (FGFR3) gene is known as a key mol. event in both oncogenesis and cell proliferation of low-grade noninvasive human bladder urothelial carcinoma (UC), which is characterized by frequent intravesical recurrence.  In this study, we investigated the antitumor potentiality of 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a small-mol. FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines.  In our in vitro cell proliferation assay, PD173074 suppressed cell proliferation remarkably in two cell lines, namely, UM-UC-14 and MGHU3, which expressed mutated FGFR3 protein.  In contrast, the other six cell lines expressing wild-type FGFR3 or without FGFR3 expression were resistant to PD173074 treatment.  Cell cycle anal. revealed the growth inhibitory effect of PD173074 was assocd. with arrest at G1-S transition in a dose-depending manner.  Furthermore, we obsd. an inverse relationship between Ki-67 and p27/Kip1 expression after PD173074 treatment, suggesting that up-regulation of p27 recruited UC cells harboring activating FGFR3 mutations in G1 that was analogous with the other receptor TKIs acting on the epidermal growth factor receptors.  In the mouse xenograft models using s.c. transplanted UM-UC-14 and MGHU3, orally administered PD173074 suppressed tumor growth and induced apoptotic changes comparable with the results of our in vitro assay.  These findings elucidated the effectiveness of mol. targeted approach for bladder UC harboring FGFR3 mutations and the potential utility to decrease the intravesical recurrence of nonmuscle invasive bladder UC after transurethral surgical resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3iBYPmq78UbVg90H21EOLACvtfcHk0liasRh5kaJzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFCjsr4%253D&md5=6af8103612a233be05d1f36aa70ff6f2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.162768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.162768%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DKawashima%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DAnai%26aufirst%3DS.%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DHirao%26aufirst%3DY.%26aulast%3DSugano%26aufirst%3DK.%26atitle%3D1-tert-Butyl-3-%255B6-%25283%252C5-dimethoxy-phenyl%2529-2-%25284-diethylamino-butylamino%2529-pyrido%255B2%252C3-d%255Dpyrimidin-7-yl%255D-urea%2520%2528PD173074%2529%252C%2520a%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptor-3%2520%2528FGFR3%2529%252C%2520inhibits%2520cell%2520proliferation%2520of%2520bladder%2520cancer%2520carrying%2520the%2520FGFR3%2520gene%2520mutation%2520along%2520with%2520up-regulation%2520of%2520p27%252FKip1%2520and%2520G1%252FG0%2520arrest%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26spage%3D795%26epage%3D802%26doi%3D10.1124%2Fjpet.109.162768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeze, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span> </span><span class="NLM_article-title">Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span><span class="refDoi"> DOI: 10.1016/j.str.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2Fj.str.2014.09.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1764-1774&author=J.+A.+Tuckerauthor=T.+Kleinauthor=J.+Breedauthor=A.+L.+Breezeauthor=R.+Overmanauthor=C.+Phillipsauthor=R.+A.+Norman&title=Structural+insights+into+FGFR+kinase+isoform+selectivity%3A+diverse+binding+modes+of+AZD4547+and+ponatinib+in+complex+with+FGFR1+and+FGFR4&doi=10.1016%2Fj.str.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOverman%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26atitle%3DStructural%2520insights%2520into%2520FGFR%2520kinase%2520isoform%2520selectivity%253A%2520diverse%2520binding%2520modes%2520of%2520AZD4547%2520and%2520ponatinib%2520in%2520complex%2520with%2520FGFR1%2520and%2520FGFR4%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26spage%3D1764%26epage%3D1774%26doi%3D10.1016%2Fj.str.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fabbro, D.</span><span> </span><span class="NLM_article-title">25 Years of small molecular weight kinase inhibitors: potentials and limitations</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1124/mol.114.095489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1124%2Fmol.114.095489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25549667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=766-775&author=D.+Fabbro&title=25+Years+of+small+molecular+weight+kinase+inhibitors%3A+potentials+and+limitations&doi=10.1124%2Fmol.114.095489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of small molecular weight kinase inhibitors: potentials and limitations</span></div><div class="casAuthors">Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">766-775</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular disorders.  Protein kinases and lipid kinases represent, therefore, an important target for the pharmaceutical industry.  In fact, approx. one-third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  To date, 30 kinase inhibitors have been approved, which, with few exceptions, are mainly for oncol. indications and directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped.  Despite these successes in kinase drug discovery, the development of kinase inhibitors with outstanding selectivity, identification and validation of driver kinase(s) in diseases, and the emerging problem of resistance to the inhibition of key target kinases remain major challenges.  This mini review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhF-9NQJx7bVg90H21EOLACvtfcHk0ljQtvR7_TMfdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D&md5=6422b036e4e447379ac6c608662954c2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.095489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.095489%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3D25%2520Years%2520of%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%253A%2520potentials%2520and%2520limitations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D766%26epage%3D775%26doi%3D10.1124%2Fmol.114.095489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">Debio 1347–101 Phase I trial in advanced solid tumours with fibroblast growth factor receptor (FGFR) alterations</span>. Clinical Trials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT01948297" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01948297</a> (November 15th, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Debio+1347%E2%80%93101+Phase+I+trial+in+advanced+solid+tumours+with+fibroblast+growth+factor+receptor+%28FGFR%29+alterations.+Clinical+Trials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01948297+%28November+15th%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DDebio%25201347%25E2%2580%2593101%2520Phase%2520I%2520trial%2520in%2520advanced%2520solid%2520tumours%2520with%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520alterations%26jtitle%3DClinical%2520Trials.gov" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nicolas-Metral, V.; Vaslin, A.; Supko, J. G.; Nakai, K.; Ishii, N.; Menetrey, A.; Roubaudi-Fraschini, M.-C.; Marfurt, J.; Chabaud, S.; Layer, A.; Purcea, D.; Douchain, J.; Zanna, C.</span><span> </span><span class="NLM_article-title">Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients</span>. Proceedings of American Association for Cancer Resarch (AACR) 106th Annual Meeting 2015, Philadelphia, PA, April 18-22, 2015; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nicolas-Metral%2C+V.%3B+Vaslin%2C+A.%3B+Supko%2C+J.+G.%3B+Nakai%2C+K.%3B+Ishii%2C+N.%3B+Menetrey%2C+A.%3B+Roubaudi-Fraschini%2C+M.-C.%3B+Marfurt%2C+J.%3B+Chabaud%2C+S.%3B+Layer%2C+A.%3B+Purcea%2C+D.%3B+Douchain%2C+J.%3B+Zanna%2C+C.+Formulation+switch+and+pharmacokinetics%2Fpharmacodynamics+of+Debio+1347+%28CH5183284%29%2C+a+novel+FGFR+inhibitor%2C+in+a+first-in-human+dose+escalation+trial+in+solid+tumors+patients.+Proceedings+of+American+Association+for+Cancer+Resarch+%28AACR%29+106th+Annual+Meeting+2015%2C+Philadelphia%2C+PA%2C+April+18-22%2C+2015%3B+AACR%3A+Philadelphia%2C+PA."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas-Metral%26aufirst%3DV.%26atitle%3DFormulation%2520switch%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520Debio%25201347%2520%2528CH5183284%2529%252C%2520a%2520novel%2520FGFR%2520inhibitor%252C%2520in%2520a%2520first-in-human%2520dose%2520escalation%2520trial%2520in%2520solid%2520tumors%2520patients%26jtitle%3DAmerican%2520Association%2520for%2520Cancer%2520Resarch%2520%2528AACR%2529%2520106th%2520Annual%2520Meeting%25202015%26pub%3DAACR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Taka, N.; Ohmori, M.; Takami, K.; Matsushita, M.; Hayase, T.; Hyodo, I.; Kochi, M.; Nishii, H.; Ebiike, H.; Nakanishi, Y.; Mio, T.; Wang, L.; Zhao, W.</span><span> </span><span class="NLM_article-title">Aminopyrazole derivative</span>. JP5225470B2, July 3,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Taka&author=M.+Ohmori&author=K.+Takami&author=M.+Matsushita&author=T.+Hayase&author=I.+Hyodo&author=M.+Kochi&author=H.+Nishii&author=H.+Ebiike&author=Y.+Nakanishi&author=T.+Mio&author=L.+Wang&author=W.+Zhao&title=Aminopyrazole+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaka%26aufirst%3DN.%26atitle%3DAminopyrazole%2520derivative%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petukhov, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2692</span><span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0ljQtvR7_TMfdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span> </span><span class="NLM_article-title">An efficient Pd-catalyzed coupling of hydrazine derivatives with aryl halides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">2555</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.1055/s-0030-1260337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1055%2Fs-0030-1260337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=2555-2558&author=F.+Maauthor=Z.+Pengauthor=W.+Liauthor=X.+Xieauthor=Z.+Zhang&title=An+efficient+Pd-catalyzed+coupling+of+hydrazine+derivatives+with+aryl+halides&doi=10.1055%2Fs-0030-1260337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1260337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1260337%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DAn%2520efficient%2520Pd-catalyzed%2520coupling%2520of%2520hydrazine%2520derivatives%2520with%2520aryl%2520halides%26jtitle%3DSynlett%26date%3D2011%26volume%3D2011%26spage%3D2555%26epage%3D2558%26doi%3D10.1055%2Fs-0030-1260337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><div class="note"><p class="first last">A 3D model structure of compound <b>1</b> and FGFR1 was generated by using DiscoveryStudio 4.1. The crystal structure of binary complex of p38α and RO3201195 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BAQ">2BAQ</a>) was superimposed at hinge region of FGFR1.</p></div><span class="NLM_contrib-group">Sullivan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holdgate, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timms, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeze, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermingham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauptit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embrey, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanScyoc, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, W. H. J.</span><span> </span><span class="NLM_article-title">Prevention of MKK6-dependent activation by binding to p38α MAP kinase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">16475</span><span class="NLM_x">–</span> <span class="NLM_lpage">16490</span><span class="refDoi"> DOI: 10.1021/bi051714v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi051714v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1emsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=16475-16490&author=J.+E.+Sullivanauthor=G.+A.+Holdgateauthor=D.+Campbellauthor=D.+Timmsauthor=S.+Gerhardtauthor=J.+Breedauthor=A.+L.+Breezeauthor=A.+Berminghamauthor=R.+A.+Pauptitauthor=R.+A.+Normanauthor=K.+J.+Embreyauthor=J.+Readauthor=W.+S.+VanScyocauthor=W.+H.+J.+Ward&title=Prevention+of+MKK6-dependent+activation+by+binding+to+p38%CE%B1+MAP+kinase&doi=10.1021%2Fbi051714v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of MKK6-Dependent Activation by Binding to p38α MAP Kinase</span></div><div class="casAuthors">Sullivan, Jane E.; Holdgate, Geoffrey A.; Campbell, Douglas; Timms, David; Gerhardt, Stefan; Breed, Jason; Breeze, Alexander L.; Bermingham, Alun; Pauptit, Richard A.; Norman, Richard A.; Embrey, Kevin J.; Read, Jon; VanScyoc, Wendy S.; Ward, Walter H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">16475-16490</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of p38α MAP kinase is a potential approach for the treatment of inflammatory disorders.  MKK6-dependent phosphorylation of the activation loop of p38α increases its catalytic activity and affinity for ATP.  An inhibitor, BIRB796, binds at a site used by the purine moiety of ATP and extends into a "selectivity pocket", which is not used by ATP.  It displaces the Asp168-Phe169-Gly170 motif at the start of the activation loop, promoting a "DFG-out" conformation.  Some other inhibitors bind only in the purine site, with p38α remaining in a "DFG-in" conformation.  We now demonstrate that selectivity pocket compds. prevent MKK6-dependent activation of p38α in addn. to inhibiting catalysis by activated p38α.  Inhibitors using only the purine site do not prevent MKK6-dependent activation.  We present kinetic analyses of seven inhibitors, whose crystal structures as complexes with p38α have been detd.  This work includes four new crystal structures and a novel assay to measure Kd for nonactivated p38α.  Selectivity pocket compds. assoc. with p38α over 30-fold more slowly than purine site compds., apparently due to low abundance of the DFG-out conformation.  At concns. that inhibit cellular prodn. of an inflammatory cytokine, TNFα, selectivity pocket compds. decrease levels of phosphorylated p38α and β.  Stabilization of a DFG-out conformation appears to interfere with recognition of p38α as a substrate by MKK6.  ATP competes less effectively for prevention of activation than for inhibition of catalysis.  By binding to a different conformation of the enzyme, compds. that prevent activation offer an alternative approach to modulation of p38α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxqU7KQtOfNrVg90H21EOLACvtfcHk0lhJY_nk5R0s-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1emsLfN&md5=3cd22c79fc33c9ce2f93aa5ae6595d2e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbi051714v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi051714v%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DJ.%2BE.%26aulast%3DHoldgate%26aufirst%3DG.%2BA.%26aulast%3DCampbell%26aufirst%3DD.%26aulast%3DTimms%26aufirst%3DD.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DBermingham%26aufirst%3DA.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DEmbrey%26aufirst%3DK.%2BJ.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DVanScyoc%26aufirst%3DW.%2BS.%26aulast%3DWard%26aufirst%3DW.%2BH.%2BJ.%26atitle%3DPrevention%2520of%2520MKK6-dependent%2520activation%2520by%2520binding%2520to%2520p38%25CE%25B1%2520MAP%2520kinase%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D16475%26epage%3D16490%26doi%3D10.1021%2Fbi051714v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Soriano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geske, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, A.</span><span> </span><span class="NLM_article-title">Targeted disruption of the <i>c-src</i> proto-oncogene leads to osteopetrosis in mice</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">702</span><span class="refDoi"> DOI: 10.1016/0092-8674(91)90499-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2F0092-8674%2891%2990499-O" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=693-702&author=P.+Sorianoauthor=C.+Montgomeryauthor=R.+Geskeauthor=A.+Bradley&title=Targeted+disruption+of+the+c-src+proto-oncogene+leads+to+osteopetrosis+in+mice&doi=10.1016%2F0092-8674%2891%2990499-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990499-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990499-O%26sid%3Dliteratum%253Aachs%26aulast%3DSoriano%26aufirst%3DP.%26aulast%3DMontgomery%26aufirst%3DC.%26aulast%3DGeske%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DA.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520c-src%2520proto-oncogene%2520leads%2520to%2520osteopetrosis%2520in%2520mice%26jtitle%3DCell%26date%3D1991%26volume%3D64%26spage%3D693%26epage%3D702%26doi%3D10.1016%2F0092-8674%2891%2990499-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemist’s guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5061</span><span class="NLM_x">–</span> <span class="NLM_lpage">5084</span><span class="refDoi"> DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0lhJY_nk5R0s-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanaro, N.</span><span> </span><span class="NLM_article-title">Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.2165/00002018-200225040-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.2165%2F00002018-200225040-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=11994029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslKktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=263-286&author=F.+De+Pontiauthor=E.+Poluzziauthor=A.+Cavalliauthor=M.+Recanatiniauthor=N.+Montanaro&title=Safety+of+non-antiarrhythmic+drugs+that+prolong+the+QT+interval+or+induce+torsade+de+pointes%3A+an+overview&doi=10.2165%2F00002018-200225040-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview</span></div><div class="casAuthors">De Ponti, Fabrizio; Poluzzi, Elisabetta; Cavalli, Andrea; Recanatini, Maurizio; Montanaro, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-286</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The long and growing list of non-antiarrhythmic drugs assocd. with prolongation of the QT interval of the ECG has generated concern not only for regulatory interventions leading to drug withdrawal, but also for the unjustified view that QT prolongation is usually an intrinsic effect of a whole therapeutic class [e.g. histamine H1 receptor antagonists (antihistamines)], whereas, in many cases, it is displayed only by some compds. within a given class of non-antiarrhythmic drugs because of an effect on cardiac repolarization.  The authors provide an overview of the different classes of non-antiarrhythmic drugs reported to prolong the QT interval (e.g. antihistamines, antipsychotics, antidepressants, and macrolides) and discusses the clin. relevance of the QT prolonging effect.  Drug-induced torsade de pointes are sometimes considered idiosyncratic, totally unpredictable adverse drug reactions, whereas a no. of risk factors for their occurrence is now recognized.  Widespread knowledge of these risk factors and implementation of a comprehensive list of QT prolonging drugs becomes an important issue.  Risk factors include congenital long QT syndrome, clin. significant bradycardia or heart disease, electrolyte imbalance (esp. hypokalemia, hypomagnesemia, hypocalcemia), impaired hepatic/renal function, concomitant treatment with other drugs with known potential for pharmacokinetic/pharmacodynamic interactions (e.g. azole antifungals, macrolide antibacterials and class I or III antiarrhythmic agents).  This review provides insight into the strategies that should be followed during a drug development program when a drug is suspected to affect the QT interval.  The factors limiting the predictive value of preclin. and clin. studies are also outlined.  The sensitivity of preclin. tests (i.e. their ability to label as pos. those drugs with a real risk of inducing QT prolongation in humans) is sufficiently good, but their specificity (i.e. their ability to label as neg. those drugs carrying no risk) is not well established.  Verapamil is a notable example of a false pos.: it blocks human ether-a-go-go-related (HERG) K+ channels, but is reported to have little potential to trigger torsade de pointes.  Although inhibition of HERG K+ channels was proposed as a primary test for screening purposes, it is important to remember that several ion currents are involved in the generation of the cardiac potential and that metabolites must be specifically tested in this in vitro test.  At the present state of knowledge, no preclin. model has an abs. predictive value or can be considered as a gold std.  Therefore, the use of several models facilitates decision making and is recommended by most experts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdiydVWOAlLbVg90H21EOLACvtfcHk0lhrB3B-Tkr0rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslKktro%253D&md5=062b6c29c8d9c42d6c6e5f6fa764b1a4</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2165%2F00002018-200225040-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200225040-00004%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMontanaro%26aufirst%3DN.%26atitle%3DSafety%2520of%2520non-antiarrhythmic%2520drugs%2520that%2520prolong%2520the%2520QT%2520interval%2520or%2520induce%2520torsade%2520de%2520pointes%253A%2520an%2520overview%26jtitle%3DDrug%2520Saf.%26date%3D2002%26volume%3D25%26spage%3D263%26epage%3D286%26doi%3D10.2165%2F00002018-200225040-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van Noord, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eijgelsheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker, B. H.</span><span> </span><span class="NLM_article-title">Drug- and non-drug-associated QT interval prolongation</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2010.03660.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1111%2Fj.1365-2125.2010.03660.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=20642543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1emsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=16-23&author=C.+van+Noordauthor=M.+Eijgelsheimauthor=B.+H.+Stricker&title=Drug-+and+non-drug-associated+QT+interval+prolongation&doi=10.1111%2Fj.1365-2125.2010.03660.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug- and non-drug-associated QT interval prolongation</span></div><div class="casAuthors">van Noord, Charlotte; Eijgelsheim, Mark; Stricker, Bruno H. Ch.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Sudden cardiac death is among the most common causes of cardiovascular death in developed countries.  The majority of sudden cardiac deaths are caused by acute ventricular arrhythmia following repolarization disturbances.  An important risk factor for repolarization disturbances is use of QT prolonging drugs, probably partly explained by gene-drug interactions.  In this review, we will summarize QT interval physiol., known risk factors for QT prolongation, including drugs and the contribution of pharmacogenetics.  The long QT syndrome can be congenital or acquired.  The congenital long QT syndrome is caused by mutations in ion channel subunits or regulatory protein coding genes and is a rare monogenic disorder with a mendelian pattern of inheritance.  Apart from that, several common genetic variants that are assocd. with QT interval duration have been identified.  Acquired QT prolongation is more prevalent than the congenital form.  Several risk factors have been identified with use of QT prolonging drugs as the most frequent cause.  Most drugs that prolong the QT interval act by blocking hERG-encoded potassium channels, although some drugs mainly modify sodium channels.  Both pharmacodynamic as well as pharmacokinetic mechanisms may be responsible for QT prolongation.  Pharmacokinetic interactions often involve drugs that are metabolized by cytochrome P 450 enzymes.  Pharmacodynamic gene-drug interactions are due to genetic variants that potentiate the QT prolonging effect of drugs.  QT prolongation, often due to use of QT prolonging drugs, is a major public health issue.  Recently, common genetic variants assocd. with QT prolongation have been identified.  Few pharmacogenetic studies have been performed to establish the genetic background of acquired QT prolongation but addnl. studies in this newly developing field are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzyy2JTFkqQLVg90H21EOLACvtfcHk0lhrB3B-Tkr0rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1emsrg%253D&md5=784c2dbd68ad4514fb606f58623c100a</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2010.03660.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2010.03660.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNoord%26aufirst%3DC.%26aulast%3DEijgelsheim%26aufirst%3DM.%26aulast%3DStricker%26aufirst%3DB.%2BH.%26atitle%3DDrug-%2520and%2520non-drug-associated%2520QT%2520interval%2520prolongation%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D70%26spage%3D16%26epage%3D23%26doi%3D10.1111%2Fj.1365-2125.2010.03660.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Haverkamp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breithardt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antzelevitch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escande, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R.</span><span> </span><span class="NLM_article-title">The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a policy conference of the European society of cardiology</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.1016/S0008-6363(00)00119-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2FS0008-6363%2800%2900119-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=219-233&author=W.+Haverkampauthor=G.+Breithardtauthor=A.+J.+Cammauthor=M.+J.+Janseauthor=M.+R.+Rosenauthor=C.+Antzelevitchauthor=D.+Escandeauthor=M.+Franzauthor=M.+Malikauthor=A.+Mossauthor=R.+Shah&title=The+potential+for+QT+prolongation+and+pro-arrhythmia+by+non-anti-arrhythmic+drugs%3A+clinical+and+regulatory+implications+report+on+a+policy+conference+of+the+European+society+of+cardiology&doi=10.1016%2FS0008-6363%2800%2900119-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2800%2900119-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252800%252900119-X%26sid%3Dliteratum%253Aachs%26aulast%3DHaverkamp%26aufirst%3DW.%26aulast%3DBreithardt%26aufirst%3DG.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DJanse%26aufirst%3DM.%2BJ.%26aulast%3DRosen%26aufirst%3DM.%2BR.%26aulast%3DAntzelevitch%26aufirst%3DC.%26aulast%3DEscande%26aufirst%3DD.%26aulast%3DFranz%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DR.%26atitle%3DThe%2520potential%2520for%2520QT%2520prolongation%2520and%2520pro-arrhythmia%2520by%2520non-anti-arrhythmic%2520drugs%253A%2520clinical%2520and%2520regulatory%2520implications%2520report%2520on%2520a%2520policy%2520conference%2520of%2520the%2520European%2520society%2520of%2520cardiology%26jtitle%3DCardiovasc.%2520Res.%26date%3D2000%26volume%3D47%26spage%3D219%26epage%3D233%26doi%3D10.1016%2FS0008-6363%2800%2900119-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lhftJh0mL46_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lhftJh0mL46_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Röder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus Müller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span><span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Klaus+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lgKSTUih99YFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKlaus%2BM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Nakanishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebiike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span> </span><span class="NLM_article-title">The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2547</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F1535-7163.MCT-14-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25169980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2547-2558&author=Y.+Nakanishiauthor=N.+Akiyamaauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=H.+Saseauthor=T.+Isobeauthor=K.+Morikamiauthor=H.+Shindohauthor=T.+Mioauthor=H.+Ebiikeauthor=N.+Takaauthor=Y.+Aokiauthor=N.+Ishii&title=The+fibroblast+growth+factor+receptor+genetic+status+as+a+potential+predictor+of+the+sensitivity+to+CH5183284%2FDebio+1347%2C+a+novel+selective+FGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-14-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor</span></div><div class="casAuthors">Nakanishi, Yoshito; Akiyama, Nukinori; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Sase, Hitoshi; Isobe, Takehito; Morikami, Kenji; Shindoh, Hidetoshi; Mio, Toshiyuki; Ebiike, Hirosato; Taka, Naoki; Aoki, Yuko; Ishii, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The FGF receptors (FGFR) are tyrosine kinases that are constitutively activated in a subset of tumors by genetic alterations such as gene amplifications, point mutations, or chromosomal translocations/rearrangements.  Recently, small-mol. inhibitors that can inhibit the FGFR family as well as the VEGF receptor (VEGFR) or platelet-derived growth factor receptor (PDGFR) family displayed clin. benefits in cohorts of patients with FGFR genetic alterations.  However, to achieve more potent and prolonged activity in such populations, a selective FGFR inhibitor is still needed.  Here, we report the identification of CH5183284/Debio 1347, a selective and orally available FGFR1, FGFR2, and FGFR3 inhibitor that has a unique chem. scaffold.  By interacting with unique residues in the ATP-binding site of FGFR1, FGFR2, or FGFR3, CH5183284/Debio 1347 selectively inhibits FGFR1, FGFR2, and FGFR3 but does not inhibit kinase insert domain receptor (KDR) or other kinases.  Consistent with its high selectivity for FGFR enzymes, CH5183284/Debio 1347 displayed preferential antitumor activity against cancer cells with various FGFR genetic alterations in a panel of 327 cancer cell lines and in xenograft models.  Because of its unique binding mode, CH5183284/Debio 1347 can inhibit FGFR2 harboring one type of the gatekeeper mutation that causes resistance to other FGFR inhibitors and block FGFR2 V564F-driven tumor growth.  CH5183284/Debio 1347 is under clin. investigation for the treatment of patients harboring FGFR genetic alterations.  Mol Cancer Ther; 13(11); 2547-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIBEnK21337Vg90H21EOLACvtfcHk0lgKSTUih99YFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F&md5=35629d891a421582022b0f6ae0496479</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0248%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSase%26aufirst%3DH.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520receptor%2520genetic%2520status%2520as%2520a%2520potential%2520predictor%2520of%2520the%2520sensitivity%2520to%2520CH5183284%252FDebio%25201347%252C%2520a%2520novel%2520selective%2520FGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2547%26epage%3D2558%26doi%3D10.1158%2F1535-7163.MCT-14-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Guthrie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garippa, R.</span><span> </span><span class="NLM_article-title">A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the IonWorks HT system</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1177/1087057105280566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1177%2F1087057105280566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=16234341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=832-840&author=H.+Guthrieauthor=F.+S.+Livingstonauthor=U.+Gublerauthor=R.+Garippa&title=A+place+for+high-throughput+electrophysiology+in+cardiac+safety%3A+screening+hERG+cell+lines+and+novel+compounds+with+the+IonWorks+HT+system&doi=10.1177%2F1087057105280566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the Ion Works HT system</span></div><div class="casAuthors">Guthrie, Heather; Livingston, Frederick S.; Gubler, Ueli; Garippa, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Several com. available pharmaceutical compds. have been shown to block the IKr current of the cardiac action potential.  This effect can cause a prolongation of the ECG QT interval and a delay in ventricular repolarization.  The Food and Drug Administration recommends that all new potential drug candidates be assessed for IKr block to avoid a potentially lethal cardiac arrhythmia known as torsades de pointes.  Direct compd. interaction with the human ether-a-go-go-related gene (hERG) product, a delayed rectifier potassium channel, has been identified as a mol. mechanism of IKr block.  One strategy to identify compds. with hERG liability is to monitor hERG current inhibition using electrophysiol. techniques.  The authors describe the IonWorks HT instrument as a tool for screening cell lines expressing hERG channels.  Based on current amplitude and stability criteria, a cell line was selected and used to perform a 300-compd. screen.  The screen was able to identify compds. with hERG activity within projects that spanned different therapeutic areas.  The cell line selection and optimization, as well as the screening abilities of the IonWorks HT system, provide a powerful means of assessing hERG active compds. early in the drug discovery pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIv_HZi0K-ybVg90H21EOLACvtfcHk0lgKSTUih99YFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVCruw%253D%253D&md5=174586a2d9c9db09d998fcfb2f54eac0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1177%2F1087057105280566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057105280566%26sid%3Dliteratum%253Aachs%26aulast%3DGuthrie%26aufirst%3DH.%26aulast%3DLivingston%26aufirst%3DF.%2BS.%26aulast%3DGubler%26aufirst%3DU.%26aulast%3DGarippa%26aufirst%3DR.%26atitle%3DA%2520place%2520for%2520high-throughput%2520electrophysiology%2520in%2520cardiac%2520safety%253A%2520screening%2520hERG%2520cell%2520lines%2520and%2520novel%2520compounds%2520with%2520the%2520IonWorks%2520HT%2520system%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2005%26volume%3D10%26spage%3D832%26epage%3D840%26doi%3D10.1177%2F1087057105280566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9085-9104. <a href="https://doi.org/10.1021/acs.jmedchem.7b01843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252B%252528FGFR%252529%252BInhibitors%26aulast%3DWang%26aufirst%3DYuming%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D16032018%26date%3D09032018%26volume%3D61%26issue%3D20%26spage%3D9085%26epage%3D9104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Ran</span>, <span class="hlFld-ContribAuthor ">Jun  Zeng</span>, <span class="hlFld-ContribAuthor ">Guoquan  Wan</span>, <span class="hlFld-ContribAuthor ">Xiaojie  He</span>, <span class="hlFld-ContribAuthor ">Zhanzhan  Feng</span>, <span class="hlFld-ContribAuthor ">Wang  Xiang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Xiang  Hu</span>, <span class="hlFld-ContribAuthor ">Ningyu  Wang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Luoting  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113499. <a href="https://doi.org/10.1016/j.ejmech.2021.113499" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113499%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluations%252Bof%252Ba%252Bseries%252Bof%252BPyrido%25255B1%25252C2-a%25255Dpyrimidinone%252Bderivatives%252Bas%252Bnovel%252Bselective%252BFGFR%252Binhibitors%26aulast%3DRan%26aufirst%3DKai%26date%3D2021%26volume%3D220%26spage%3D113499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">The Design and Application of Bioisosteres in Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-81. <a href="https://doi.org/10.1002/0471266949.bmc259" title="DOI URL">https://doi.org/10.1002/0471266949.bmc259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc259%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bin%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D81%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdellah  Yamani</span>, <span class="hlFld-ContribAuthor ">Daria  Zdżalik-Bielecka</span>, <span class="hlFld-ContribAuthor ">Joanna  Lipner</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Stańczak</span>, <span class="hlFld-ContribAuthor ">Natalia  Piórkowska</span>, <span class="hlFld-ContribAuthor ">Paulina Seweryna  Stańczak</span>, <span class="hlFld-ContribAuthor ">Patrycja  Olejkowska</span>, <span class="hlFld-ContribAuthor ">Joanna  Hucz-Kalitowska</span>, <span class="hlFld-ContribAuthor ">Marta  Magdycz</span>, <span class="hlFld-ContribAuthor ">Karolina  Dzwonek</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Dubiel</span>, <span class="hlFld-ContribAuthor ">Monika  Lamparska-Przybysz</span>, <span class="hlFld-ContribAuthor ">Delfina  Popiel</span>, <span class="hlFld-ContribAuthor ">Jerzy  Pieczykolan</span>, <span class="hlFld-ContribAuthor ">Maciej  Wieczorek</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112990. <a href="https://doi.org/10.1016/j.ejmech.2020.112990" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112990%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Bnovel%252Bpyrazole-benzimidazole%252BCPL304110%25252C%252Bas%252Ba%252Bpotent%252Band%252Bselective%252Binhibitor%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptors%252BFGFR%252B%2525281%2525E2%252580%2525933%252529%26aulast%3DYamani%26aufirst%3DAbdellah%26date%3D2021%26volume%3D210%26spage%3D112990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongnan  Xu</span>, <span class="hlFld-ContribAuthor ">Yuqing  Wang</span>, <span class="hlFld-ContribAuthor ">Yucheng  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhixing  Huang</span>, <span class="hlFld-ContribAuthor ">Lutz  Ackermann</span>, <span class="hlFld-ContribAuthor ">Zhixiong  Ruan</span>. </span><span class="cited-content_cbyCitation_article-title">Manganese- and rhenium-catalyzed C–H enaminylation: expedient access to novel indole–purine hybrids with anti-tumor bioactivities. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (22)
                                     , 3709-3714. <a href="https://doi.org/10.1039/D0QO01120G" title="DOI URL">https://doi.org/10.1039/D0QO01120G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01120G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01120G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DManganese-%252Band%252Brhenium-catalyzed%252BC%2525E2%252580%252593H%252Benaminylation%25253A%252Bexpedient%252Baccess%252Bto%252Bnovel%252Bindole%2525E2%252580%252593purine%252Bhybrids%252Bwith%252Banti-tumor%252Bbioactivities%26aulast%3DXu%26aufirst%3DZhongnan%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D22%26spage%3D3709%26epage%3D3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Niefang  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (11)
                                     , 1330-1341. <a href="https://doi.org/10.2174/1570180817999200608140628" title="DOI URL">https://doi.org/10.2174/1570180817999200608140628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180817999200608140628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180817999200608140628%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%25253A%252B5-amino-1H-pyrazole-1-%252Bcarbonyl%252Bderivatives%252Bas%252BFGFR%252BInhibitors%26aulast%3DZhang%26aufirst%3DYan%26date%3D2020%26volume%3D17%26issue%3D11%26spage%3D1330%26epage%3D1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Niu</span>, <span class="hlFld-ContribAuthor ">Peng‐Bo  Bai</span>, <span class="hlFld-ContribAuthor ">Qin‐Xin  Lou</span>, <span class="hlFld-ContribAuthor ">Shang‐Dong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of a Key Synthon of Indole Alkaloid Synthesis by Palladium(II)‐Catalyzed Indole 2‐Methylenephosphorylation. </span><span class="cited-content_cbyCitation_journal-name">ChemCatChem</span><span> <strong>2020,</strong> <em>12 </em>
                                    (14)
                                     , 3644-3649. <a href="https://doi.org/10.1002/cctc.202000415" title="DOI URL">https://doi.org/10.1002/cctc.202000415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cctc.202000415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcctc.202000415%26sid%3Dliteratum%253Aachs%26jtitle%3DChemCatChem%26atitle%3DGeneration%252Bof%252Ba%252BKey%252BSynthon%252Bof%252BIndole%252BAlkaloid%252BSynthesis%252Bby%252BPalladium%252528II%252529%2525E2%252580%252590Catalyzed%252BIndole%252B2%2525E2%252580%252590Methylenephosphorylation%26aulast%3DNiu%26aufirst%3DYuan%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D14%26spage%3D3644%26epage%3D3649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhang  Wu</span>, <span class="hlFld-ContribAuthor ">Lingzi  Chen</span>, <span class="hlFld-ContribAuthor ">Liping  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Zhaojun  Dong</span>, <span class="hlFld-ContribAuthor ">Qian  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Wei</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Wulan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of potent and stable short peptide FGFR1 antagonist for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>143 </em>, 105179. <a href="https://doi.org/10.1016/j.ejps.2019.105179" title="DOI URL">https://doi.org/10.1016/j.ejps.2019.105179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2019.105179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2019.105179%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DThe%252Bdiscovery%252Bof%252Bpotent%252Band%252Bstable%252Bshort%252Bpeptide%252BFGFR1%252Bantagonist%252Bfor%252Bcancer%252Btherapy%26aulast%3DWu%26aufirst%3DJianzhang%26date%3D2020%26volume%3D143%26spage%3D105179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>151 </em>, 104567. <a href="https://doi.org/10.1016/j.phrs.2019.104567" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104567%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B%252528FGFR%252529%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%252Bincluding%252Bthose%252Bof%252Bthe%252Burinary%252Bbladder%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D151%26spage%3D104567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna  Volynets</span>, <span class="hlFld-ContribAuthor ">Sergiy  Lukashov</span>, <span class="hlFld-ContribAuthor ">Iryna  Borysenko</span>, <span class="hlFld-ContribAuthor ">Andrii  Gryshchenko</span>, <span class="hlFld-ContribAuthor ">Sergiy  Starosyla</span>, <span class="hlFld-ContribAuthor ">Volodymyr  Bdzhola</span>, <span class="hlFld-ContribAuthor ">Tetiana  Ruban</span>, <span class="hlFld-ContribAuthor ">Anna  Iatsyshyna</span>, <span class="hlFld-ContribAuthor ">Lyubov  Lukash</span>, <span class="hlFld-ContribAuthor ">Yaroslav  Bilokin</span>, <span class="hlFld-ContribAuthor ">Sergiy  Yarmoluk</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2019,</strong> <em>150 </em>
                                    (10)
                                     , 1801-1808. <a href="https://doi.org/10.1007/s00706-019-02493-5" title="DOI URL">https://doi.org/10.1007/s00706-019-02493-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-019-02493-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-019-02493-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DIdentification%252Bof%252Bprotein%252Bkinase%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B1%252B%252528FGFR1%252529%252Binhibitors%252Bamong%252Bthe%252Bderivatives%252Bof%252B5-%2525285%25252C6-dimethoxybenzimidazol-1-yl%252529-3-hydroxythiophene-2-carboxylic%252Bacid%26aulast%3DVolynets%26aufirst%3DGalyna%26date%3D2019%26date%3D2019%26volume%3D150%26issue%3D10%26spage%3D1801%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Lin-jiang  Tong</span>, <span class="hlFld-ContribAuthor ">Bai-you  Tang</span>, <span class="hlFld-ContribAuthor ">Hong-yan  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xian-wen  Cao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Hong-lin  Li</span>, <span class="hlFld-ContribAuthor ">Xu-hong  Qian</span>, <span class="hlFld-ContribAuthor ">Yu-fang  Xu</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2019,</strong> <em>40 </em>
                                    (6)
                                     , 823-832. <a href="https://doi.org/10.1038/s41401-018-0191-7" title="DOI URL">https://doi.org/10.1038/s41401-018-0191-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-018-0191-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-018-0191-7%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DC11%25252C%252Ba%252Bnovel%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B1%252B%252528FGFR1%252529%252Binhibitor%25252C%252Bsuppresses%252Bbreast%252Bcancer%252Bmetastasis%252Band%252Bangiogenesis%26aulast%3DChen%26aufirst%3DZhuo%26date%3D2019%26date%3D2018%26volume%3D40%26issue%3D6%26spage%3D823%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hitoshi  Sase</span>, <span class="hlFld-ContribAuthor ">Yoshito  Nakanishi</span>, <span class="hlFld-ContribAuthor ">Satoshi  Aida</span>, <span class="hlFld-ContribAuthor ">Kana  Horiguchi-Takei</span>, <span class="hlFld-ContribAuthor ">Nukinori  Akiyama</span>, <span class="hlFld-ContribAuthor ">Toshihiko  Fujii</span>, <span class="hlFld-ContribAuthor ">Kiyoaki  Sakata</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Mio</span>, <span class="hlFld-ContribAuthor ">Masahiro  Aoki</span>, <span class="hlFld-ContribAuthor ">Nobuya  Ishii</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in
              FGFR2
              -Amplified Gastric Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (10)
                                     , 2217-2225. <a href="https://doi.org/10.1158/1535-7163.MCT-17-1022" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-1022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-1022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-1022%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAcquired%252BJHDM1D%2525E2%252580%252593BRAF%252BFusion%252BConfers%252BResistance%252Bto%252BFGFR%252BInhibition%252Bin%252BFGFR2%252B-Amplified%252BGastric%252BCancer%26aulast%3DSase%26aufirst%3DHitoshi%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D2217%26epage%3D2225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You-Lu  Pan</span>, <span class="hlFld-ContribAuthor ">Yan-Ling  Liu</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (4)
                                     , 767. <a href="https://doi.org/10.3390/molecules23040767" title="DOI URL">https://doi.org/10.3390/molecules23040767</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23040767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23040767%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DComputational%252BSimulation%252BStudies%252Bon%252Bthe%252BBinding%252BSelectivity%252Bof%252B1-%2525281H-Benzimidazol-5-yl%252529-5-aminopyrazoles%252Bin%252BComplexes%252Bwith%252BFGFR1%252Band%252BFGFR4%26aulast%3DPan%26aufirst%3DYou-Lu%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D4%26spage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan  Jiang</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Wei</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Yuchi  Ma</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 698. <a href="https://doi.org/10.3390/molecules23030698" title="DOI URL">https://doi.org/10.3390/molecules23030698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23030698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23030698%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStructure-Based%252BDiscovery%252Bof%252Ba%252BSeries%252Bof%252B5H-Pyrrolo%25255B2%25252C3-b%25255Dpyrazine%252BFGFR%252BKinase%252BInhibitors%26aulast%3DJiang%26aufirst%3DAlan%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zixin  Xie</span>, <span class="hlFld-ContribAuthor ">Donghua  Cheng</span>, <span class="hlFld-ContribAuthor ">Lu  Luo</span>, <span class="hlFld-ContribAuthor ">Guoliang  Shen</span>, <span class="hlFld-ContribAuthor ">Suwei  Pan</span>, <span class="hlFld-ContribAuthor ">Yaqian  Pan</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Xuebao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Faqing  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 905-919. <a href="https://doi.org/10.1080/14756366.2018.1460824" title="DOI URL">https://doi.org/10.1080/14756366.2018.1460824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1460824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1460824%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-bromo-N-%2525283%25252C5-dimethoxyphenyl%252529benzamide%252Bderivatives%252Bas%252Bnovel%252BFGFR1%252Binhibitors%252Bfor%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DXie%26aufirst%3DZixin%26date%3D2018%26date%3D2018%26volume%3D33%26issue%3D1%26spage%3D905%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anver Basha  Shaik</span>, <span class="hlFld-ContribAuthor ">Garikapati Koteswara  Rao</span>, <span class="hlFld-ContribAuthor ">G. Bharath  Kumar</span>, <span class="hlFld-ContribAuthor ">Nibeditha  Patel</span>, <span class="hlFld-ContribAuthor ">Vangala Santhosh  Reddy</span>, <span class="hlFld-ContribAuthor ">Irfan  Khan</span>, <span class="hlFld-ContribAuthor ">Sunitha Rani  Routhu</span>, <span class="hlFld-ContribAuthor ">C. Ganesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Immadi  Veena</span>, <span class="hlFld-ContribAuthor ">Kunta  Chandra Shekar</span>, <span class="hlFld-ContribAuthor ">Madan  Barkume</span>, <span class="hlFld-ContribAuthor ">Shailesh  Jadhav</span>, <span class="hlFld-ContribAuthor ">Aarti  Juvekar</span>, <span class="hlFld-ContribAuthor ">Jyoti  Kode</span>, <span class="hlFld-ContribAuthor ">Manika  Pal-Bhadra</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 305-324. <a href="https://doi.org/10.1016/j.ejmech.2017.07.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazolochalcones%252Bas%252Bpotential%252Bmodulators%252Bof%252BPI3K%25252FAkt%25252FmTOR%252Bpathway%252Band%252Binducers%252Bof%252Bapoptosis%252Bin%252Bbreast%252Bcancer%252Bcells%26aulast%3DShaik%26aufirst%3DAnver%2BBasha%26date%3D2017%26volume%3D139%26spage%3D305%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueqiang  Li</span>, <span class="hlFld-ContribAuthor ">Christopher P.  Guise</span>, <span class="hlFld-ContribAuthor ">Rana  Taghipouran</span>, <span class="hlFld-ContribAuthor ">Yuliana  Yosaatmadja</span>, <span class="hlFld-ContribAuthor ">Amir  Ashoorzadeh</span>, <span class="hlFld-ContribAuthor ">Woo-Kyong  Paik</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Squire</span>, <span class="hlFld-ContribAuthor ">Shuang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Adam V.  Patterson</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>135 </em>, 531-543. <a href="https://doi.org/10.1016/j.ejmech.2017.04.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Oxo-3%25252C%252B4-dihydropyrimido%25255B4%25252C%252B5-%252Bd%252B%25255Dpyrimidinyl%252Bderivatives%252Bas%252Bnew%252Birreversible%252Bpan%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B%252528FGFR%252529%252Binhibitors%26aulast%3DLi%26aufirst%3DXueqiang%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Aminopyrazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LHMDS, MeCN, THF −78 °C; (b) DMF-DMA; (c) Ar<sup>2</sup>NHNH<sub>2</sub> HCl, 100 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Indole Aminopyrazole Derivatives (<b>4</b>–<b>15</b> and <b>17</b>–<b>19</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, ArylSO<sub>2</sub>Cl, THF; (b) LHMDS, MeCN, THF −78 °C; (c) DMF-DMA; (d) Ar<sup>2</sup>NHNH<sub>2</sub> HCl, 100 °C.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LHMDS, MeCN, THF −78 °C; (b) DMF-DMA, THF; (c) ArNHNH<sub>2</sub> HCl, 100 °C; (d) sodium methanesulfinate, CuI, <i>N</i>1,<i>N</i>2-dimethylcyclohexane-1,2-diamine, DMSO, 120 °C.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of aryl Hydrazines (<b>7a</b>, <b>9c</b>, <b>10c</b>, <b>11c</b>, and <b>12a</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>, Pd-C, H<sub>2</sub>O-EtOH; (b) NaNO<sub>2</sub>, dil. HCl then SnCl<sub>2</sub>, 0 °C; (c) Pd<sub>2</sub>dba<sub>3</sub>, <i>t</i>-Bu XPhos, BocNHNHBoc, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C; (d) 4 M HCl-AcOEt.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure analysis of 3D modeling of <b>1</b> (magenta) and FGFR1. The side chains of amino acid residues important for ligand recognition of FGFR1 are highlighted as sticks (green). Hydrogen bonds at hinge region and backpocket region are indicated in blue dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A, B) Neighboring amino acid residues of FGFR1 (green), KDR (magenta), and SRC (cyan) around <b>4</b> (orange). The binding models were created by overlapping X-ray structures of FGFR1 (2FGI), KDR (3WZD), and SRC (3G5D). (C, D) Superimposed structures of <b>4</b> (purple) and <b>8</b> (green) in FGFR1. The hydrogen bonds between <b>8</b> and FGFR1 (E531 and D641) are indicated in blue dotted lines. The benzimidazole in <b>8</b> interacts better with V561, I545, and F641 by CH−π interaction (orange dotted lines) than phenoxy group in <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. p<i>K</i><sub>a</sub> values of amines in the solvent exposed region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/medium/jm-2016-01156k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. 3D structures of <b>8</b>, <b>21</b>, and <b>22</b>. (A) The X-ray crystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>) of <b>8</b> (purple) and FGFR1. The side chains of the amino acid residues important for ligand recognition of FGFR1 are highlighted as sticks (green). Hydrogen bonds are indicated in blue dotted lines. The CH−π and S−π interactions are indicated in orange dotted lines. (B) The overlapped structure of <b>8</b> (green), FGFR1 (green), KDR (magenta), and SRC (light blue). The side chains of the amino acid residues around <b>8</b> in the backpocket regions are reported as sticks. (C) The overlapped structure of <b>8</b> (magenta), <b>21</b> (light blue), and <b>22</b> (green) in FGFR1. The side chains of the amino acid residues around <b>8</b>, <b>21</b>, and <b>22</b> in the backpocket regions are reported as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01156/20161202/images/large/jm-2016-01156k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01156&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i75">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53386" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53386" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Pagliarini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.15252/embr.201439949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.15252%2Fembr.201439949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25680965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=280-296&author=R.+Pagliariniauthor=W.+Shaoauthor=W.+R.+Sellers&title=Oncogene+addiction%3A+pathways+of+therapeutic+response%2C+resistance%2C+and+road+maps+toward+a+cure&doi=10.15252%2Fembr.201439949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span></div><div class="casAuthors">Pagliarini, Raymond; Shao, Wenlin; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-296</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival.  While most cancers harbor multiple oncogenic mutations, a wealth of preclin. and clin. data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'.  Herein, we describe the clin. evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene-targeted therapies.  Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEtJj2YdGf6LVg90H21EOLACvtfcHk0lhd-LjXJSS6jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D&md5=30f0b2a45a633e12155d5c7e577753e2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.15252%2Fembr.201439949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201439949%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DOncogene%2520addiction%253A%2520pathways%2520of%2520therapeutic%2520response%252C%2520resistance%252C%2520and%2520road%2520maps%2520toward%2520a%2520cure%26jtitle%3DEMBO%2520Rep.%26date%3D2015%26volume%3D16%26spage%3D280%26epage%3D296%26doi%3D10.15252%2Fembr.201439949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Saijo, N.</span><span> </span><span class="NLM_article-title">Present status and problems on molecular targeted therapy of cancer</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.4143/crt.2012.44.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.4143%2Fcrt.2012.44.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A280%3ADC%252BC38rkslChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=1-10&author=N.+Saijo&title=Present+status+and+problems+on+molecular+targeted+therapy+of+cancer&doi=10.4143%2Fcrt.2012.44.1.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Present status and problems on molecular targeted therapy of cancer</span></div><div class="casAuthors">Saijo Nagahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Numerous clinical trials of molecular targeted drugs for cancer have been conducted, with remarkable results for certain drugs and accumulation of "negative data" causing a hitch in the development plan for some other compounds.  Five recent issues and problems of molecular targeted therapies were discussed critically.  Drug discovery and effects against driver mutations (activating mutations) and problems: possibility for circumventing inherent and acquired resistance with the aim of achieving radical cure.  Synthetic lethality: reasonable patient selection in individualized treatment strategy.  Response rate and progression-free survival improvement with or without overall survival benefit and enhancement of toxicity in bevacizumab therapy: best endpoints for the evaluation of effect of antiangiogenic therapy.  Negative data on small-molecule targeted therapy, primarily vascular endothelial growth factor tyrosine kinase inhibitors: loose GO or NO-GO decision criteria for further development of new compounds in early clinical trials.  Effect of immunotherapy: difficulty to verify by proof of principle study.  We are faced to many questions for the development of efficient personalized therapy.  Accumulation of scientific global preclinical and clinical evidences is essential to use these new therapeutic modalities for the improvement of oncologic health care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCEHsxuDVeOqqcneEtCi92fW6udTcc2eaTq4JGM5X0JLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkslChsg%253D%253D&md5=c5375ca0a4c6617c4759862d296d90e4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2012.44.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2012.44.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DSaijo%26aufirst%3DN.%26atitle%3DPresent%2520status%2520and%2520problems%2520on%2520molecular%2520targeted%2520therapy%2520of%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D44%26spage%3D1%26epage%3D10%26doi%3D10.4143%2Fcrt.2012.44.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Walker, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, A. H.</span><span> </span><span class="NLM_article-title">Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2224</span><span class="NLM_x">–</span> <span class="NLM_lpage">2236</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i9.2224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.3748%2Fwjg.v20.i9.2224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlOnsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2224-2236&author=E.+J.+Walkerauthor=A.+H.+Ko&title=Beyond+first-line+chemotherapy+for+advanced+pancreatic+cancer%3A+an+expanding+array+of+therapeutic+options%3F&doi=10.3748%2Fwjg.v20.i9.2224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?</span></div><div class="casAuthors">Walker, Evan J.; Ko, Andrew H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2224-2236</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  While an increasing no. of therapeutic options are now available for the first-line treatment of locally advanced or metastatic pancreatic cancer, the optimal choice for treatment in the second-line setting and beyond is less well defined.  A variety of cytotoxic agents, either alone or in combination, have been evaluated, although primarily in the context of small single-arm or retrospective studies.  Most regimens have been assocd. with median progression-free survival rates in the range of 2-4 mo and overall survival rates between 4-8 mo, highlighting the very poor prognosis of patients who are candidates for such treatment.  Targeted therapies studied in this chemotherapy-refractory setting, meanwhile, have produced even worse efficacy results.  In the current article, we review the clin. evidence for treatment of refractory disease, primarily in patients who have progressed on front-line gemcitabine-based chemotherapy.  In the process, we highlight the limitations of the available data to date as well as some of the challenges in designing appropriate clin. trials in this salvage setting, including how to select an appropriate control arm given the absence of a wellestablished ref. std., and the importance of incorporating predictive biomarkers and quality of life measures whenever possible into study design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRwFSWHsYM_7Vg90H21EOLACvtfcHk0lhd-LjXJSS6jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlOnsLjK&md5=2018712a8e7bed3ca5be83f8fd66b2e3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i9.2224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i9.2224%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BJ.%26aulast%3DKo%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520first-line%2520chemotherapy%2520for%2520advanced%2520pancreatic%2520cancer%253A%2520an%2520expanding%2520array%2520of%2520therapeutic%2520options%253F%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D2224%26epage%3D2236%26doi%3D10.3748%2Fwjg.v20.i9.2224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Dieci, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnedos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0lgg4wtgtEAGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lgg4wtgtEAGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalenc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Garcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deudon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yovine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3693</span><span class="NLM_x">–</span> <span class="NLM_lpage">3702</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F1078-0432.CCR-13-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=23658459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3693-3702&author=F.+Andreauthor=T.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+Turnerauthor=H.+Rugoauthor=J.+W.+Smithauthor=S.+Deudonauthor=M.+Shiauthor=Y.+Zhangauthor=A.+Kayauthor=G.+D.+Portaauthor=A.+Yovineauthor=J.+Baselga&title=Targeting+FGFR+with+dovitinib+%28TKI258%29%3A+preclinical+and+clinical+data+in+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer</span></div><div class="casAuthors">Andre, Fabrice; Bachelot, Thomas; Campone, Mario; Dalenc, Florence; Perez-Garcia, Jose M.; Hurvitz, Sara A.; Turner, Nicholas; Rugo, Hope; Smith, John W.; Deudon, Stephanie; Shi, Michael; Zhang, Yong; Kay, Andrea; Graus Porta, Diana; Yovine, Alejandro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3693-3702</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are obsd. in approx. 10% of breast cancers and are related to poor outcomes.  We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers.  Exptl. Design: Preclin. activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2).  Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-neg. metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.  FGFR1 amplification was assessed by silver in situ hybridization.  Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quant. PCR (qPCR).  Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines.  Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.  Eighty-one patients were enrolled in the trial.  Unconfirmed response or stable disease for more than 6 mo was obsd. in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-pos. and FGFR1-nonamplified/HR-pos. breast cancer.  When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-pos. patients, the mean redn. in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.  Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification.  Clin Cancer Res; 19(13); 3693-702. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqsUkPK9d9YrVg90H21EOLACvtfcHk0lgg4wtgtEAGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fK&md5=8c6e6a67540e15a67ea71c93eeda92a9</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0190%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%2BW.%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DG.%2BD.%26aulast%3DYovine%26aufirst%3DA.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeting%2520FGFR%2520with%2520dovitinib%2520%2528TKI258%2529%253A%2520preclinical%2520and%2520clinical%2520data%2520in%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3693%26epage%3D3702%26doi%3D10.1158%2F1078-0432.CCR-13-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F0008-5472.CAN-04-4409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+P.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+J%C3%BCrgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+a+highly+potent%2C+orally+bioavailable%2C+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F0008-5472.CAN-04-4409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4409%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400%26doi%3D10.1158%2F0008-5472.CAN-04-4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Launay-Vacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deray, G.</span><span> </span><span class="NLM_article-title">Hypertension and proteinuria: a class-effect of antiangiogenic therapies</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e3283161012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1097%2FCAD.0b013e3283161012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=81-82&author=V.+Launay-Vacherauthor=G.+Deray&title=Hypertension+and+proteinuria%3A+a+class-effect+of+antiangiogenic+therapies&doi=10.1097%2FCAD.0b013e3283161012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e3283161012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e3283161012%26sid%3Dliteratum%253Aachs%26aulast%3DLaunay-Vacher%26aufirst%3DV.%26aulast%3DDeray%26aufirst%3DG.%26atitle%3DHypertension%2520and%2520proteinuria%253A%2520a%2520class-effect%2520of%2520antiangiogenic%2520therapies%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D81%26epage%3D82%26doi%3D10.1097%2FCAD.0b013e3283161012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gavine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0ljujYYz78Dedg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudge, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span> </span><span class="NLM_article-title">Protein–ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5012</span><span class="refDoi"> DOI: 10.1021/jm3004043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5003-5012&author=R.+A.+Normanauthor=A.-K.+Schottauthor=D.+M.+Andrewsauthor=J.+Breedauthor=K.+M.+Footeauthor=A.+P.+Garnerauthor=D.+Oggauthor=J.+P.+Ormeauthor=J.+H.+Pinkauthor=K.+Robertsauthor=D.+A.+Rudgeauthor=A.+P.+Thomasauthor=A.+G.+Leach&title=Protein%E2%80%93ligand+crystal+structures+can+guide+the+design+of+selective+inhibitors+of+the+FGFR+tyrosine+kinase&doi=10.1021%2Fjm3004043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Fjm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004043%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DSchott%26aufirst%3DA.-K.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26atitle%3DProtein%25E2%2580%2593ligand%2520crystal%2520structures%2520can%2520guide%2520the%2520design%2520of%2520selective%2520inhibitors%2520of%2520the%2520FGFR%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5003%26epage%3D5012%26doi%3D10.1021%2Fjm3004043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Yosaatmadja, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, C. J.</span><span> </span><span class="NLM_article-title">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1107/S1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25760602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+%C3%85+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2FS1399004714027539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Patterson, Adam Vorn; Smaill, Jeff Bruce; Squire, Christopher John</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-533</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">1399-0047</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family are expressed widely in normal tissues and play a role in tissue repair, inflammation, angiogenesis and development.  However, aberrant signalling through this family can lead to cellular proliferation, evasion of apoptosis and induction of angiogenesis, which is implicated in the development of many cancers and also in drug resistance.  The high frequency of FGFR amplification or mutation in multiple cancer types is such that this family has been targeted for the discovery of novel, selective drug compds., with one of the most recently discovered being AZD4547, a subnanomolar (IC50) FGFR1 inhibitor developed by AstraZeneca and currently in clin. trials.  The 1.65 Å resoln. crystal structure of AZD4547 bound to the kinase domain of FGFR1 has been detd. and reveals extensive drug-protein interactions, an integral network of water mols. and the tight closure of the FGFR1 P-loop to form a long, narrow crevice in which the AZD4547 mol. binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjQbdbZHvbhbVg90H21EOLACvtfcHk0lgOsnIQebmWxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFalu7Y%253D&md5=e7afc5e7d14f6879fee79b998a46e0b4</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520%25C3%2585%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2FS1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, D. G.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+G.+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0lgOsnIQebmWxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Miyake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugano, K.</span><span> </span><span class="NLM_article-title">1-<i>tert</i>-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-<i>d</i>]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G<sub>1</sub>/G<sub>0</sub> arrest</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1124/jpet.109.162768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1124%2Fjpet.109.162768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=19955487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFCjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=795-802&author=M.+Miyakeauthor=M.+Ishiiauthor=N.+Koyamaauthor=K.+Kawashimaauthor=T.+Kodamaauthor=S.+Anaiauthor=K.+Fujimotoauthor=Y.+Hiraoauthor=K.+Sugano&title=1-tert-Butyl-3-%5B6-%283%2C5-dimethoxy-phenyl%29-2-%284-diethylamino-butylamino%29-pyrido%5B2%2C3-d%5Dpyrimidin-7-yl%5D-urea+%28PD173074%29%2C+a+selective+tyrosine+kinase+inhibitor+of+fibroblast+growth+factor+receptor-3+%28FGFR3%29%2C+inhibits+cell+proliferation+of+bladder+cancer+carrying+the+FGFR3+gene+mutation+along+with+up-regulation+of+p27%2FKip1+and+G1%2FG0+arrest&doi=10.1124%2Fjpet.109.162768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest</span></div><div class="casAuthors">Miyake, Makito; Ishii, Masazumi; Koyama, Naoki; Kawashima, Kiyotaka; Kodama, Tetsuro; Anai, Satoshi; Fujimoto, Kiyohide; Hirao, Yoshihiko; Sugano, Kokichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-802</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activating mutation of the fibroblast growth factor receptor-3 (FGFR3) gene is known as a key mol. event in both oncogenesis and cell proliferation of low-grade noninvasive human bladder urothelial carcinoma (UC), which is characterized by frequent intravesical recurrence.  In this study, we investigated the antitumor potentiality of 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a small-mol. FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines.  In our in vitro cell proliferation assay, PD173074 suppressed cell proliferation remarkably in two cell lines, namely, UM-UC-14 and MGHU3, which expressed mutated FGFR3 protein.  In contrast, the other six cell lines expressing wild-type FGFR3 or without FGFR3 expression were resistant to PD173074 treatment.  Cell cycle anal. revealed the growth inhibitory effect of PD173074 was assocd. with arrest at G1-S transition in a dose-depending manner.  Furthermore, we obsd. an inverse relationship between Ki-67 and p27/Kip1 expression after PD173074 treatment, suggesting that up-regulation of p27 recruited UC cells harboring activating FGFR3 mutations in G1 that was analogous with the other receptor TKIs acting on the epidermal growth factor receptors.  In the mouse xenograft models using s.c. transplanted UM-UC-14 and MGHU3, orally administered PD173074 suppressed tumor growth and induced apoptotic changes comparable with the results of our in vitro assay.  These findings elucidated the effectiveness of mol. targeted approach for bladder UC harboring FGFR3 mutations and the potential utility to decrease the intravesical recurrence of nonmuscle invasive bladder UC after transurethral surgical resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3iBYPmq78UbVg90H21EOLACvtfcHk0lhJLlYPsarQ8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFCjsr4%253D&md5=6af8103612a233be05d1f36aa70ff6f2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.162768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.162768%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DKawashima%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DAnai%26aufirst%3DS.%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DHirao%26aufirst%3DY.%26aulast%3DSugano%26aufirst%3DK.%26atitle%3D1-tert-Butyl-3-%255B6-%25283%252C5-dimethoxy-phenyl%2529-2-%25284-diethylamino-butylamino%2529-pyrido%255B2%252C3-d%255Dpyrimidin-7-yl%255D-urea%2520%2528PD173074%2529%252C%2520a%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptor-3%2520%2528FGFR3%2529%252C%2520inhibits%2520cell%2520proliferation%2520of%2520bladder%2520cancer%2520carrying%2520the%2520FGFR3%2520gene%2520mutation%2520along%2520with%2520up-regulation%2520of%2520p27%252FKip1%2520and%2520G1%252FG0%2520arrest%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26spage%3D795%26epage%3D802%26doi%3D10.1124%2Fjpet.109.162768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeze, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span> </span><span class="NLM_article-title">Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span><span class="refDoi"> DOI: 10.1016/j.str.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2Fj.str.2014.09.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1764-1774&author=J.+A.+Tuckerauthor=T.+Kleinauthor=J.+Breedauthor=A.+L.+Breezeauthor=R.+Overmanauthor=C.+Phillipsauthor=R.+A.+Norman&title=Structural+insights+into+FGFR+kinase+isoform+selectivity%3A+diverse+binding+modes+of+AZD4547+and+ponatinib+in+complex+with+FGFR1+and+FGFR4&doi=10.1016%2Fj.str.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOverman%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26atitle%3DStructural%2520insights%2520into%2520FGFR%2520kinase%2520isoform%2520selectivity%253A%2520diverse%2520binding%2520modes%2520of%2520AZD4547%2520and%2520ponatinib%2520in%2520complex%2520with%2520FGFR1%2520and%2520FGFR4%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26spage%3D1764%26epage%3D1774%26doi%3D10.1016%2Fj.str.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fabbro, D.</span><span> </span><span class="NLM_article-title">25 Years of small molecular weight kinase inhibitors: potentials and limitations</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1124/mol.114.095489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1124%2Fmol.114.095489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25549667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=766-775&author=D.+Fabbro&title=25+Years+of+small+molecular+weight+kinase+inhibitors%3A+potentials+and+limitations&doi=10.1124%2Fmol.114.095489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of small molecular weight kinase inhibitors: potentials and limitations</span></div><div class="casAuthors">Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">766-775</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular disorders.  Protein kinases and lipid kinases represent, therefore, an important target for the pharmaceutical industry.  In fact, approx. one-third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  To date, 30 kinase inhibitors have been approved, which, with few exceptions, are mainly for oncol. indications and directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped.  Despite these successes in kinase drug discovery, the development of kinase inhibitors with outstanding selectivity, identification and validation of driver kinase(s) in diseases, and the emerging problem of resistance to the inhibition of key target kinases remain major challenges.  This mini review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhF-9NQJx7bVg90H21EOLACvtfcHk0lhJLlYPsarQ8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D&md5=6422b036e4e447379ac6c608662954c2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.095489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.095489%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3D25%2520Years%2520of%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%253A%2520potentials%2520and%2520limitations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D766%26epage%3D775%26doi%3D10.1124%2Fmol.114.095489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">Debio 1347–101 Phase I trial in advanced solid tumours with fibroblast growth factor receptor (FGFR) alterations</span>. Clinical Trials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT01948297" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01948297</a> (November 15th, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Debio+1347%E2%80%93101+Phase+I+trial+in+advanced+solid+tumours+with+fibroblast+growth+factor+receptor+%28FGFR%29+alterations.+Clinical+Trials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01948297+%28November+15th%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DDebio%25201347%25E2%2580%2593101%2520Phase%2520I%2520trial%2520in%2520advanced%2520solid%2520tumours%2520with%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520alterations%26jtitle%3DClinical%2520Trials.gov" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nicolas-Metral, V.; Vaslin, A.; Supko, J. G.; Nakai, K.; Ishii, N.; Menetrey, A.; Roubaudi-Fraschini, M.-C.; Marfurt, J.; Chabaud, S.; Layer, A.; Purcea, D.; Douchain, J.; Zanna, C.</span><span> </span><span class="NLM_article-title">Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients</span>. Proceedings of American Association for Cancer Resarch (AACR) 106th Annual Meeting 2015, Philadelphia, PA, April 18-22, 2015; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nicolas-Metral%2C+V.%3B+Vaslin%2C+A.%3B+Supko%2C+J.+G.%3B+Nakai%2C+K.%3B+Ishii%2C+N.%3B+Menetrey%2C+A.%3B+Roubaudi-Fraschini%2C+M.-C.%3B+Marfurt%2C+J.%3B+Chabaud%2C+S.%3B+Layer%2C+A.%3B+Purcea%2C+D.%3B+Douchain%2C+J.%3B+Zanna%2C+C.+Formulation+switch+and+pharmacokinetics%2Fpharmacodynamics+of+Debio+1347+%28CH5183284%29%2C+a+novel+FGFR+inhibitor%2C+in+a+first-in-human+dose+escalation+trial+in+solid+tumors+patients.+Proceedings+of+American+Association+for+Cancer+Resarch+%28AACR%29+106th+Annual+Meeting+2015%2C+Philadelphia%2C+PA%2C+April+18-22%2C+2015%3B+AACR%3A+Philadelphia%2C+PA."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas-Metral%26aufirst%3DV.%26atitle%3DFormulation%2520switch%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520Debio%25201347%2520%2528CH5183284%2529%252C%2520a%2520novel%2520FGFR%2520inhibitor%252C%2520in%2520a%2520first-in-human%2520dose%2520escalation%2520trial%2520in%2520solid%2520tumors%2520patients%26jtitle%3DAmerican%2520Association%2520for%2520Cancer%2520Resarch%2520%2528AACR%2529%2520106th%2520Annual%2520Meeting%25202015%26pub%3DAACR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Taka, N.; Ohmori, M.; Takami, K.; Matsushita, M.; Hayase, T.; Hyodo, I.; Kochi, M.; Nishii, H.; Ebiike, H.; Nakanishi, Y.; Mio, T.; Wang, L.; Zhao, W.</span><span> </span><span class="NLM_article-title">Aminopyrazole derivative</span>. JP5225470B2, July 3,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Taka&author=M.+Ohmori&author=K.+Takami&author=M.+Matsushita&author=T.+Hayase&author=I.+Hyodo&author=M.+Kochi&author=H.+Nishii&author=H.+Ebiike&author=Y.+Nakanishi&author=T.+Mio&author=L.+Wang&author=W.+Zhao&title=Aminopyrazole+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaka%26aufirst%3DN.%26atitle%3DAminopyrazole%2520derivative%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petukhov, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2692</span><span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0lgYKcdHGo3DcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span> </span><span class="NLM_article-title">An efficient Pd-catalyzed coupling of hydrazine derivatives with aryl halides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">2555</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.1055/s-0030-1260337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1055%2Fs-0030-1260337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=2555-2558&author=F.+Maauthor=Z.+Pengauthor=W.+Liauthor=X.+Xieauthor=Z.+Zhang&title=An+efficient+Pd-catalyzed+coupling+of+hydrazine+derivatives+with+aryl+halides&doi=10.1055%2Fs-0030-1260337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1260337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1260337%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DAn%2520efficient%2520Pd-catalyzed%2520coupling%2520of%2520hydrazine%2520derivatives%2520with%2520aryl%2520halides%26jtitle%3DSynlett%26date%3D2011%26volume%3D2011%26spage%3D2555%26epage%3D2558%26doi%3D10.1055%2Fs-0030-1260337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><div class="note"><p class="first last">A 3D model structure of compound <b>1</b> and FGFR1 was generated by using DiscoveryStudio 4.1. The crystal structure of binary complex of p38α and RO3201195 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BAQ">2BAQ</a>) was superimposed at hinge region of FGFR1.</p></div><span class="NLM_contrib-group">Sullivan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holdgate, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timms, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeze, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermingham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauptit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embrey, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanScyoc, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, W. H. J.</span><span> </span><span class="NLM_article-title">Prevention of MKK6-dependent activation by binding to p38α MAP kinase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">16475</span><span class="NLM_x">–</span> <span class="NLM_lpage">16490</span><span class="refDoi"> DOI: 10.1021/bi051714v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi051714v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1emsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=16475-16490&author=J.+E.+Sullivanauthor=G.+A.+Holdgateauthor=D.+Campbellauthor=D.+Timmsauthor=S.+Gerhardtauthor=J.+Breedauthor=A.+L.+Breezeauthor=A.+Berminghamauthor=R.+A.+Pauptitauthor=R.+A.+Normanauthor=K.+J.+Embreyauthor=J.+Readauthor=W.+S.+VanScyocauthor=W.+H.+J.+Ward&title=Prevention+of+MKK6-dependent+activation+by+binding+to+p38%CE%B1+MAP+kinase&doi=10.1021%2Fbi051714v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of MKK6-Dependent Activation by Binding to p38α MAP Kinase</span></div><div class="casAuthors">Sullivan, Jane E.; Holdgate, Geoffrey A.; Campbell, Douglas; Timms, David; Gerhardt, Stefan; Breed, Jason; Breeze, Alexander L.; Bermingham, Alun; Pauptit, Richard A.; Norman, Richard A.; Embrey, Kevin J.; Read, Jon; VanScyoc, Wendy S.; Ward, Walter H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">16475-16490</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of p38α MAP kinase is a potential approach for the treatment of inflammatory disorders.  MKK6-dependent phosphorylation of the activation loop of p38α increases its catalytic activity and affinity for ATP.  An inhibitor, BIRB796, binds at a site used by the purine moiety of ATP and extends into a "selectivity pocket", which is not used by ATP.  It displaces the Asp168-Phe169-Gly170 motif at the start of the activation loop, promoting a "DFG-out" conformation.  Some other inhibitors bind only in the purine site, with p38α remaining in a "DFG-in" conformation.  We now demonstrate that selectivity pocket compds. prevent MKK6-dependent activation of p38α in addn. to inhibiting catalysis by activated p38α.  Inhibitors using only the purine site do not prevent MKK6-dependent activation.  We present kinetic analyses of seven inhibitors, whose crystal structures as complexes with p38α have been detd.  This work includes four new crystal structures and a novel assay to measure Kd for nonactivated p38α.  Selectivity pocket compds. assoc. with p38α over 30-fold more slowly than purine site compds., apparently due to low abundance of the DFG-out conformation.  At concns. that inhibit cellular prodn. of an inflammatory cytokine, TNFα, selectivity pocket compds. decrease levels of phosphorylated p38α and β.  Stabilization of a DFG-out conformation appears to interfere with recognition of p38α as a substrate by MKK6.  ATP competes less effectively for prevention of activation than for inhibition of catalysis.  By binding to a different conformation of the enzyme, compds. that prevent activation offer an alternative approach to modulation of p38α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxqU7KQtOfNrVg90H21EOLACvtfcHk0lgYKcdHGo3DcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1emsLfN&md5=3cd22c79fc33c9ce2f93aa5ae6595d2e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbi051714v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi051714v%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DJ.%2BE.%26aulast%3DHoldgate%26aufirst%3DG.%2BA.%26aulast%3DCampbell%26aufirst%3DD.%26aulast%3DTimms%26aufirst%3DD.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DBermingham%26aufirst%3DA.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DEmbrey%26aufirst%3DK.%2BJ.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DVanScyoc%26aufirst%3DW.%2BS.%26aulast%3DWard%26aufirst%3DW.%2BH.%2BJ.%26atitle%3DPrevention%2520of%2520MKK6-dependent%2520activation%2520by%2520binding%2520to%2520p38%25CE%25B1%2520MAP%2520kinase%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D16475%26epage%3D16490%26doi%3D10.1021%2Fbi051714v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Soriano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geske, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, A.</span><span> </span><span class="NLM_article-title">Targeted disruption of the <i>c-src</i> proto-oncogene leads to osteopetrosis in mice</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">702</span><span class="refDoi"> DOI: 10.1016/0092-8674(91)90499-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2F0092-8674%2891%2990499-O" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=693-702&author=P.+Sorianoauthor=C.+Montgomeryauthor=R.+Geskeauthor=A.+Bradley&title=Targeted+disruption+of+the+c-src+proto-oncogene+leads+to+osteopetrosis+in+mice&doi=10.1016%2F0092-8674%2891%2990499-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990499-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990499-O%26sid%3Dliteratum%253Aachs%26aulast%3DSoriano%26aufirst%3DP.%26aulast%3DMontgomery%26aufirst%3DC.%26aulast%3DGeske%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DA.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520c-src%2520proto-oncogene%2520leads%2520to%2520osteopetrosis%2520in%2520mice%26jtitle%3DCell%26date%3D1991%26volume%3D64%26spage%3D693%26epage%3D702%26doi%3D10.1016%2F0092-8674%2891%2990499-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemist’s guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5061</span><span class="NLM_x">–</span> <span class="NLM_lpage">5084</span><span class="refDoi"> DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0lhrITUy8WLqSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanaro, N.</span><span> </span><span class="NLM_article-title">Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.2165/00002018-200225040-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.2165%2F00002018-200225040-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=11994029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslKktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=263-286&author=F.+De+Pontiauthor=E.+Poluzziauthor=A.+Cavalliauthor=M.+Recanatiniauthor=N.+Montanaro&title=Safety+of+non-antiarrhythmic+drugs+that+prolong+the+QT+interval+or+induce+torsade+de+pointes%3A+an+overview&doi=10.2165%2F00002018-200225040-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview</span></div><div class="casAuthors">De Ponti, Fabrizio; Poluzzi, Elisabetta; Cavalli, Andrea; Recanatini, Maurizio; Montanaro, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-286</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The long and growing list of non-antiarrhythmic drugs assocd. with prolongation of the QT interval of the ECG has generated concern not only for regulatory interventions leading to drug withdrawal, but also for the unjustified view that QT prolongation is usually an intrinsic effect of a whole therapeutic class [e.g. histamine H1 receptor antagonists (antihistamines)], whereas, in many cases, it is displayed only by some compds. within a given class of non-antiarrhythmic drugs because of an effect on cardiac repolarization.  The authors provide an overview of the different classes of non-antiarrhythmic drugs reported to prolong the QT interval (e.g. antihistamines, antipsychotics, antidepressants, and macrolides) and discusses the clin. relevance of the QT prolonging effect.  Drug-induced torsade de pointes are sometimes considered idiosyncratic, totally unpredictable adverse drug reactions, whereas a no. of risk factors for their occurrence is now recognized.  Widespread knowledge of these risk factors and implementation of a comprehensive list of QT prolonging drugs becomes an important issue.  Risk factors include congenital long QT syndrome, clin. significant bradycardia or heart disease, electrolyte imbalance (esp. hypokalemia, hypomagnesemia, hypocalcemia), impaired hepatic/renal function, concomitant treatment with other drugs with known potential for pharmacokinetic/pharmacodynamic interactions (e.g. azole antifungals, macrolide antibacterials and class I or III antiarrhythmic agents).  This review provides insight into the strategies that should be followed during a drug development program when a drug is suspected to affect the QT interval.  The factors limiting the predictive value of preclin. and clin. studies are also outlined.  The sensitivity of preclin. tests (i.e. their ability to label as pos. those drugs with a real risk of inducing QT prolongation in humans) is sufficiently good, but their specificity (i.e. their ability to label as neg. those drugs carrying no risk) is not well established.  Verapamil is a notable example of a false pos.: it blocks human ether-a-go-go-related (HERG) K+ channels, but is reported to have little potential to trigger torsade de pointes.  Although inhibition of HERG K+ channels was proposed as a primary test for screening purposes, it is important to remember that several ion currents are involved in the generation of the cardiac potential and that metabolites must be specifically tested in this in vitro test.  At the present state of knowledge, no preclin. model has an abs. predictive value or can be considered as a gold std.  Therefore, the use of several models facilitates decision making and is recommended by most experts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdiydVWOAlLbVg90H21EOLACvtfcHk0lhrITUy8WLqSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslKktro%253D&md5=062b6c29c8d9c42d6c6e5f6fa764b1a4</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2165%2F00002018-200225040-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200225040-00004%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMontanaro%26aufirst%3DN.%26atitle%3DSafety%2520of%2520non-antiarrhythmic%2520drugs%2520that%2520prolong%2520the%2520QT%2520interval%2520or%2520induce%2520torsade%2520de%2520pointes%253A%2520an%2520overview%26jtitle%3DDrug%2520Saf.%26date%3D2002%26volume%3D25%26spage%3D263%26epage%3D286%26doi%3D10.2165%2F00002018-200225040-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van Noord, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eijgelsheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker, B. H.</span><span> </span><span class="NLM_article-title">Drug- and non-drug-associated QT interval prolongation</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2010.03660.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1111%2Fj.1365-2125.2010.03660.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=20642543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1emsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=16-23&author=C.+van+Noordauthor=M.+Eijgelsheimauthor=B.+H.+Stricker&title=Drug-+and+non-drug-associated+QT+interval+prolongation&doi=10.1111%2Fj.1365-2125.2010.03660.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug- and non-drug-associated QT interval prolongation</span></div><div class="casAuthors">van Noord, Charlotte; Eijgelsheim, Mark; Stricker, Bruno H. Ch.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Sudden cardiac death is among the most common causes of cardiovascular death in developed countries.  The majority of sudden cardiac deaths are caused by acute ventricular arrhythmia following repolarization disturbances.  An important risk factor for repolarization disturbances is use of QT prolonging drugs, probably partly explained by gene-drug interactions.  In this review, we will summarize QT interval physiol., known risk factors for QT prolongation, including drugs and the contribution of pharmacogenetics.  The long QT syndrome can be congenital or acquired.  The congenital long QT syndrome is caused by mutations in ion channel subunits or regulatory protein coding genes and is a rare monogenic disorder with a mendelian pattern of inheritance.  Apart from that, several common genetic variants that are assocd. with QT interval duration have been identified.  Acquired QT prolongation is more prevalent than the congenital form.  Several risk factors have been identified with use of QT prolonging drugs as the most frequent cause.  Most drugs that prolong the QT interval act by blocking hERG-encoded potassium channels, although some drugs mainly modify sodium channels.  Both pharmacodynamic as well as pharmacokinetic mechanisms may be responsible for QT prolongation.  Pharmacokinetic interactions often involve drugs that are metabolized by cytochrome P 450 enzymes.  Pharmacodynamic gene-drug interactions are due to genetic variants that potentiate the QT prolonging effect of drugs.  QT prolongation, often due to use of QT prolonging drugs, is a major public health issue.  Recently, common genetic variants assocd. with QT prolongation have been identified.  Few pharmacogenetic studies have been performed to establish the genetic background of acquired QT prolongation but addnl. studies in this newly developing field are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzyy2JTFkqQLVg90H21EOLACvtfcHk0lhrITUy8WLqSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1emsrg%253D&md5=784c2dbd68ad4514fb606f58623c100a</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2010.03660.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2010.03660.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNoord%26aufirst%3DC.%26aulast%3DEijgelsheim%26aufirst%3DM.%26aulast%3DStricker%26aufirst%3DB.%2BH.%26atitle%3DDrug-%2520and%2520non-drug-associated%2520QT%2520interval%2520prolongation%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D70%26spage%3D16%26epage%3D23%26doi%3D10.1111%2Fj.1365-2125.2010.03660.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Haverkamp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breithardt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antzelevitch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escande, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R.</span><span> </span><span class="NLM_article-title">The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a policy conference of the European society of cardiology</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.1016/S0008-6363(00)00119-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2FS0008-6363%2800%2900119-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=219-233&author=W.+Haverkampauthor=G.+Breithardtauthor=A.+J.+Cammauthor=M.+J.+Janseauthor=M.+R.+Rosenauthor=C.+Antzelevitchauthor=D.+Escandeauthor=M.+Franzauthor=M.+Malikauthor=A.+Mossauthor=R.+Shah&title=The+potential+for+QT+prolongation+and+pro-arrhythmia+by+non-anti-arrhythmic+drugs%3A+clinical+and+regulatory+implications+report+on+a+policy+conference+of+the+European+society+of+cardiology&doi=10.1016%2FS0008-6363%2800%2900119-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2800%2900119-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252800%252900119-X%26sid%3Dliteratum%253Aachs%26aulast%3DHaverkamp%26aufirst%3DW.%26aulast%3DBreithardt%26aufirst%3DG.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DJanse%26aufirst%3DM.%2BJ.%26aulast%3DRosen%26aufirst%3DM.%2BR.%26aulast%3DAntzelevitch%26aufirst%3DC.%26aulast%3DEscande%26aufirst%3DD.%26aulast%3DFranz%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DR.%26atitle%3DThe%2520potential%2520for%2520QT%2520prolongation%2520and%2520pro-arrhythmia%2520by%2520non-anti-arrhythmic%2520drugs%253A%2520clinical%2520and%2520regulatory%2520implications%2520report%2520on%2520a%2520policy%2520conference%2520of%2520the%2520European%2520society%2520of%2520cardiology%26jtitle%3DCardiovasc.%2520Res.%26date%3D2000%26volume%3D47%26spage%3D219%26epage%3D233%26doi%3D10.1016%2FS0008-6363%2800%2900119-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lh8R6YeuzRIaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lh8R6YeuzRIaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Röder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus Müller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span><span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Klaus+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lg73ze2PyZrYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKlaus%2BM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Nakanishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebiike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span> </span><span class="NLM_article-title">The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2547</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1158%2F1535-7163.MCT-14-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=25169980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2547-2558&author=Y.+Nakanishiauthor=N.+Akiyamaauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=H.+Saseauthor=T.+Isobeauthor=K.+Morikamiauthor=H.+Shindohauthor=T.+Mioauthor=H.+Ebiikeauthor=N.+Takaauthor=Y.+Aokiauthor=N.+Ishii&title=The+fibroblast+growth+factor+receptor+genetic+status+as+a+potential+predictor+of+the+sensitivity+to+CH5183284%2FDebio+1347%2C+a+novel+selective+FGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-14-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor</span></div><div class="casAuthors">Nakanishi, Yoshito; Akiyama, Nukinori; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Sase, Hitoshi; Isobe, Takehito; Morikami, Kenji; Shindoh, Hidetoshi; Mio, Toshiyuki; Ebiike, Hirosato; Taka, Naoki; Aoki, Yuko; Ishii, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The FGF receptors (FGFR) are tyrosine kinases that are constitutively activated in a subset of tumors by genetic alterations such as gene amplifications, point mutations, or chromosomal translocations/rearrangements.  Recently, small-mol. inhibitors that can inhibit the FGFR family as well as the VEGF receptor (VEGFR) or platelet-derived growth factor receptor (PDGFR) family displayed clin. benefits in cohorts of patients with FGFR genetic alterations.  However, to achieve more potent and prolonged activity in such populations, a selective FGFR inhibitor is still needed.  Here, we report the identification of CH5183284/Debio 1347, a selective and orally available FGFR1, FGFR2, and FGFR3 inhibitor that has a unique chem. scaffold.  By interacting with unique residues in the ATP-binding site of FGFR1, FGFR2, or FGFR3, CH5183284/Debio 1347 selectively inhibits FGFR1, FGFR2, and FGFR3 but does not inhibit kinase insert domain receptor (KDR) or other kinases.  Consistent with its high selectivity for FGFR enzymes, CH5183284/Debio 1347 displayed preferential antitumor activity against cancer cells with various FGFR genetic alterations in a panel of 327 cancer cell lines and in xenograft models.  Because of its unique binding mode, CH5183284/Debio 1347 can inhibit FGFR2 harboring one type of the gatekeeper mutation that causes resistance to other FGFR inhibitors and block FGFR2 V564F-driven tumor growth.  CH5183284/Debio 1347 is under clin. investigation for the treatment of patients harboring FGFR genetic alterations.  Mol Cancer Ther; 13(11); 2547-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIBEnK21337Vg90H21EOLACvtfcHk0lg73ze2PyZrYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F&md5=35629d891a421582022b0f6ae0496479</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0248%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSase%26aufirst%3DH.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520receptor%2520genetic%2520status%2520as%2520a%2520potential%2520predictor%2520of%2520the%2520sensitivity%2520to%2520CH5183284%252FDebio%25201347%252C%2520a%2520novel%2520selective%2520FGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2547%26epage%3D2558%26doi%3D10.1158%2F1535-7163.MCT-14-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Guthrie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garippa, R.</span><span> </span><span class="NLM_article-title">A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the IonWorks HT system</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1177/1087057105280566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=10.1177%2F1087057105280566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=16234341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=832-840&author=H.+Guthrieauthor=F.+S.+Livingstonauthor=U.+Gublerauthor=R.+Garippa&title=A+place+for+high-throughput+electrophysiology+in+cardiac+safety%3A+screening+hERG+cell+lines+and+novel+compounds+with+the+IonWorks+HT+system&doi=10.1177%2F1087057105280566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the Ion Works HT system</span></div><div class="casAuthors">Guthrie, Heather; Livingston, Frederick S.; Gubler, Ueli; Garippa, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Several com. available pharmaceutical compds. have been shown to block the IKr current of the cardiac action potential.  This effect can cause a prolongation of the ECG QT interval and a delay in ventricular repolarization.  The Food and Drug Administration recommends that all new potential drug candidates be assessed for IKr block to avoid a potentially lethal cardiac arrhythmia known as torsades de pointes.  Direct compd. interaction with the human ether-a-go-go-related gene (hERG) product, a delayed rectifier potassium channel, has been identified as a mol. mechanism of IKr block.  One strategy to identify compds. with hERG liability is to monitor hERG current inhibition using electrophysiol. techniques.  The authors describe the IonWorks HT instrument as a tool for screening cell lines expressing hERG channels.  Based on current amplitude and stability criteria, a cell line was selected and used to perform a 300-compd. screen.  The screen was able to identify compds. with hERG activity within projects that spanned different therapeutic areas.  The cell line selection and optimization, as well as the screening abilities of the IonWorks HT system, provide a powerful means of assessing hERG active compds. early in the drug discovery pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIv_HZi0K-ybVg90H21EOLACvtfcHk0lg73ze2PyZrYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVCruw%253D%253D&md5=174586a2d9c9db09d998fcfb2f54eac0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1177%2F1087057105280566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057105280566%26sid%3Dliteratum%253Aachs%26aulast%3DGuthrie%26aufirst%3DH.%26aulast%3DLivingston%26aufirst%3DF.%2BS.%26aulast%3DGubler%26aufirst%3DU.%26aulast%3DGarippa%26aufirst%3DR.%26atitle%3DA%2520place%2520for%2520high-throughput%2520electrophysiology%2520in%2520cardiac%2520safety%253A%2520screening%2520hERG%2520cell%2520lines%2520and%2520novel%2520compounds%2520with%2520the%2520IonWorks%2520HT%2520system%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2005%26volume%3D10%26spage%3D832%26epage%3D840%26doi%3D10.1177%2F1087057105280566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V','PDB','5B7V'); return false;">PDB: 5B7V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI','PDB','2FGI'); return false;">PDB: 2FGI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WZD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WZD','PDB','2WZD'); return false;">PDB: 2WZD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D','PDB','3G5D'); return false;">PDB: 3G5D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN','PDB','4WUN'); return false;">PDB: 4WUN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0','PDB','3TT0'); return false;">PDB: 3TT0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BAQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BAQ','PDB','2BAQ'); return false;">PDB: 2BAQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01156">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46710"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01156">10.1021/acs.jmedchem.6b01156</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details and data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_001.pdf">jm6b01156_si_001.pdf (1.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01156/suppl_file/jm6b01156_si_002.csv">jm6b01156_si_002.csv (5.17 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors released the atomic coordinates and experimental data for FGFR1 complex with compound <b>8</b> in the PDB under accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5B7V">5B7V</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01156%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-23%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01156" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995f08ec623ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
